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ABSTRACT 
 
Chronic kidney disease (CKD) affects more than 30 million adults in the U.S. and 
is strongly associated with cardiovascular events and mortality. Venous 
thromboembolism (VTE) is the third leading vascular disease, affects up to 900,000 
Americans each year and contributes to as many as 100,000 deaths annually. The 
relationship of CKD and VTE has been described in patients receiving dialysis, kidney 
transplants recipients and in nephrotic syndrome, however, data supporting the 
association of VTE in mild to moderate CKD is conflicted. The overall goal of this 
research was to study the association of CKD and VTE and to understand the 
mechanisms of this association. To accomplish this goal we studied participants of the 
Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study, a 
nationally representative cohort of 30,239 blacks and whites in the U.S..  
 
The first chapter provides a review of the state-of-the science on CKD and VTE 
and potential mechanisms for this association. We focus on factor VIII as a potential 
mediator of VTE risk in CKD by reviewing the biochemistry and epidemiology linking 
factor VIII and CKD. 
 
In Chapter 2, we use a cohort study design and a competing risk analysis to 
determine the risk of VTE with albuminuria (ACR) and with various equations for 
estimated glomerular filtration rate (eGFR). There was no association of ACR and VTE 
and the risk of VTE was similar among eGFR equations. Compared to a normal eGFR 
(>90 ml/min/1.73m2), eGFR < 45 ml/min/1.73m2 was associated with a two-fold risk of 
VTE. The association of eGFR and unprovoked VTE was similar to the association with 
provoked VTE. The population attributable fraction of CKD (eGFR<60 ml/min/1.73m2) 
was modest at 5%.  
 
In Chapter 3, we utilize a case-cohort study to determine if biomarkers of 
inflammation (C-reactive protein) and procoagulation (Factor VIII and D-dimer) 
attenuate the risk of VTE in CKD. These biomarkers were higher in lower kidney 
function and were also strongly associated with VTE. Adjustment for factor VIII fully 
attenuated the risk of VTE in CKD, thus factor VIII is a potential mediator of the 
association of CKD and VTE. We assessed whether lifestyle factors and medications 
mitigate the risk of VTE in those with and without CKD. Exercise frequency and use of 
statins were associated with reduced risk of VTE in the presence and absence of CKD, 
but normal BMI was associated with reduced VTE risk only in those without CKD. 
  
We conclude that CKD is a risk factor for VTE, and findings shed light on the 
mechanisms of this association. Interventions that might lower VTE risk in CKD patients 
include exercise and statin therapy, but not weight loss. Factor VIII is a potential 
mediator of VTE in CKD and deserves further study. We suggest several avenues for 
future research to explore the relationship of Factor VIII and CKD.
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CHAPTER 1: VENOUS THROMBOEMBOLISM, FACTOR VIII AND CHRONIC 
KIDNEY DISEASE 
 
Katharine L. Cheung Larner College of Medicine, at the University of Vermont 
Beth A. Bouchard, Larner College of Medicine, at the University of Vermont 
Mary Cushman, Larner College of Medicine, at the University of Vermont 
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1.1. Abstract 
Chronic kidney disease (CKD) affects 30 million Americans and is associated 
with approximately a two-fold increased risk of venous thromboembolism (VTE). There 
is a graded increased risk of VTE across declining estimated glomerular filtration rate 
(eGFR) and increasing albuminuria, and the risk varies by cause of CKD. Compared to 
the general population, VTE in end-stage kidney disease (ESKD) is associated with 
greater hospitalization and higher mortality. Mortality associated with PE in ESKD also 
varies by cause of ESKD. Transplant patients with VTE are at a greater risk for death and 
graft loss than transplant patients without VTE. The reasons for VTE in CKD are not well 
understood but recent data suggest that Factor VIII (FVIII) is a mediator of VTE in CKD. 
FVIII is an essential cofactor in the coagulation cascade and a strong risk marker for VTE 
in general. It is inversely correlated with eGFR and prospective studies demonstrate that 
FVIII activity predicts CKD and rapid eGFR decline. This review summarizes the 
epidemiology of CKD with VTE, reviews the biochemistry and determinants of FVIII, 
including von Willebrand factor and ABO blood group, outlines the epidemiology of 
FVIII and CKD, and suggests future research directions. 
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1.2. Introduction 
Chronic kidney disease (CKD) affects 15% of the adult U.S. population and the 
prevalence is increasing, in part due to the aging population.1 The two most common 
causes of CKD are diabetes and hypertension.2 CKD can lead to important health 
consequences including anemia, metabolic acidosis, bone disease, immune dysfunction 
and lower quality of life.2 There is also an increased risk of death and cardiovascular 
events including stroke, coronary disease, heart failure and peripheral arterial disease in 
CKD.3 The heightened risk of vascular diseases in CKD is not limited to the arterial 
circulation. Emerging evidence reveals an association between CKD and venous 
thromboembolism (VTE).4-7 
VTE consists of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is 
the third leading vascular disease6,8-10 and costs the US healthcare system $7-10 billion 
each year.11 VTE affects up to 900,000 Americans annually and contributes to 60-
100,000 deaths each year.12 Approximately 25% of people who have a PE experience 
sudden death13 and for VTE the 28-day case fatality is 11%.14 Among those who 
experience a DVT, up to one-half will go on to develop chronic venous insufficiency 
and/or post thrombotic syndrome.13 Also, VTE recurs in one-third of people within ten 
years.13 About half of VTE are provoked by surgery, trauma, cancer or immobilization 
and half are unprovoked. Given that there is no identifiable provoking factor in half of all 
VTE cases, research on novel risk factors and mechanisms of VTE is important. The risk 
of VTE increases with lower kidney function,7 and VTE carries a higher risk of death in 
CKD than the general population.15 
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FVIII is an acute phase reactant16 that is elevated in stress17, inflammation18 and 
exertion.19 Elevated FVIII also represents a procoagulant state and endothelial injury. It is 
elevated with increased age, BMI, total cholesterol and in diabetes.20 FVIII is a strong 
and independent risk factor for VTE; in the Leiden Thrombophilia Study (LETS) FVIII  
150% was associated with a 5-fold increased risk of VTE compared to FVIII <100%, 
after controlling for BMI, diabetes, smoking, ABO blood group and vWF.21 FVIII 
remained a strong risk factor after controlling for fibrinogen, an acute phase reactant, and 
C-reactive protein, an inflammatory marker that is often elevated in the acute phase.22 
The reasons for VTE in CKD are not well understood. The classical 
pathophysiological explanation for VTE, as attributed to Virchow, implicated the triad of 
a hypercoagulable state, stasis of blood and vascular injury.23,24 Over the past few 
decades a greater understanding of the pathophysiology of VTE has been described 
including delineation of prothrombotic genetic factors (Factor V Leiden and prothrombin 
gene mutation 20210A),25 procoagulant and inflammatory pathways26 and the influence 
of obesity27,28 Of these risk factors, procoagulant and inflammatory pathways are 
candidate mediators for VTE in CKD given the heightened procoagulant and 
inflammatory state that accompanies CKD. As the increased risk of VTE in CKD has 
been only recently reported, little research exists studying the mechanisms of this 
association. The Multiple Environmental and Genetic Assessment of risk factors for 
venous thrombosis (MEGA) study, a case-control study of patients with VTE and 
controls, identified that the relationship between CKD and VTE could be explained by 
von Willebrand factor and Factor VIII.29 In the Reasons for Geographic And Racial 
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Differences in Stroke (REGARDS) study, a case-cohort analysis showed that Factor VIII 
completely accounted for the association between CKD and VTE.30 In this review we 
provide an overview of the epidemiology of CKD and VTE. Given the importance of 
Factor VIII in this relationship, we summarize the literature on CKD and FVIII, identify 
potential pathogenic pathways involved, discuss limitations of current literature and 
explore research gaps for future investigations. 
 
Definitions of Chronic Kidney Disease 
CKD is defined as a reduced glomerular filtration rate (GFR) or elevated 
albuminuria that is present for a minimum of three months.31 Since glomerular filtration 
rate is not easily measured in practice, estimated GFR (eGFR) is calculated based on 
equations that include serum creatinine (and or cystatin C), age, sex and race. Less 
commonly studies cited in this review defined CKD based on a threshold of serum 
creatinine (or cystatin C). For the purposes of surveillance and in most epidemiological 
studies, CKD is defined based on one measurement of eGFR or albuminuria.1 
Albuminuria is measured using the urinary albumin-to-creatinine ratio (ACR) and is 
categorized as <30 mg/g (normal to mildly increased), 30-<300 mg/g (moderately 
increased) and  300 mg/g (severely increased). The kidney has many functions beyond 
that of filtration including production of hormones such as erythropoietin and activated 
vitamin D, regulation of volume status, tonicity and pH and metabolism and excretion of 
drugs. A decline in eGFR is approximately paralleled by a decline in other kidney 
functions and is the most commonly used clinical measure of kidney function. 
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1.3. Association of Chronic Kidney Disease with Venous Thromboembolism 
Mild to moderate kidney disease and VTE 
There is growing evidence for an association of kidney disease and VTE, 
although some of the data are conflicting depending on how kidney disease was defined 
(Table 1.1). The Tromso study, which recruited community-dwelling adults age 25-84 
years old from 1994-95, found that higher serum cystatin C was associated with a 2.5-
fold increased risk of VTE over 12.5-year median follow-up.32 The Atherosclerosis Risk 
in Communities (ARIC) Study studied 10,700 self-identified white and black participants 
age 45-64 years and used cystatin C-based eGFR. As compared to eGFR 90 
ml/min/1.73m2, the adjusted hazard ratios (HRs) for eGFR 60-89 and 15-59 
ml/min/1.73m2 were 1.26 and 1.60.33 Conversely, creatinine-based eGFR was not 
associated with VTE occurrence in the ARIC study. In the Longitudinal Investigation of 
Thromboembolism (LITE) study, which combined participants from ARIC and the 
Cardiovascular Health Study (CHS), creatinine-based eGFR <60 ml/min/1.73m2 was 
associated with an increased risk of VTE in middle age and older Americans.6 Given the 
prior conflicting reports, The Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study compared the risk of VTE among 30,239 adults age 45 and older 
across the US, using different eGFR equations, including the combined creatinine-
cystatin C based eGFR. This study reported a two-fold increased risk of VTE in 
participants with creatinine-cystatin C based eGFR <45 compared to eGFR>90 
ml/min/1.73m2,7 and a similar risk for the other eGFR equations. In addition, a meta-
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analysis of five cohort studies, including LITE and Tromso, confirmed an association of 
eGFR and VTE.4 Other types of studies have reported a relationship between eGFR and 
VTE. The MEGA study was a case-control study that examined risk factors for venous 
thrombosis. This study recruited consecutive patients from 1999-2004, aged 18-70 years, 
who experienced a first VTE, and a control group. This study found an increased risk of 
VTE with eGFR < 60 ml/min/1.73m2, and this risk was augmented by additional genetic 
or acquired risk factors such as Factor V Leiden or immobilization. Interestingly, there 
was also a J-shaped relationship between eGFR and VTE, where very high eGFR was 
also associated with an increased risk of VTE.34 A large nationwide case-cohort study in 
Denmark of 128,096 patients with a hospital diagnosis of VTE demonstrated that kidney 
disease was associated with an increased risk of VTE. The risk also varied by etiology of 
kidney disease. The adjusted OR of VTE for hypertensive nephropathy was 1.41 (95% CI 
1.22, 1.63) and for nephrotic syndrome was 2.89 (95% CI 2.26, 3.69).35 In summary, 
compared to normal eGFR, the risk of VTE for CKD is approximately 1.26-2.89-fold 
depending on the definition of eGFR and etiology of CKD. 
Albuminuria has also been linked to a higher risk of VTE, even at mildly 
increased levels. In the Prevention of Renal and Vascular End-stage Disease 
(PREVEND) study, which was enriched for participants with albuminuria, as compared 
to minimal albuminuria (ACR < 30 mg/g) the adjusted HR (95% CI) of VTE for ACR 
>30 mg/g was 2.0 (1.34, 2.98).5 In contrast, there was no association of albuminuria and 
VTE in the REGARDS general population study.7 In the aforementioned meta-analysis, 
as compared to ACR 5 mg/g, the HR for VTE increased linearly across ACR: 1.34 for 
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ACR 30mg/g, 1.60 for ACR 300 mg/g and 1.92 for ACR > 1000mg/g. This is consistent 
with the marked increased risk of VTE in nephrotic syndrome,36,37 which presents with 
proteinuria >3.5 grams/day. The mechanisms promoting VTE in this disease state may be 
different. 
 
End-stage kidney disease and VTE 
There is an increased risk of VTE in patients with end-stage kidney disease 
(ESKD) although it is not clear if the risk is similar or greater than in CKD. In the 
Nationwide Inpatient Sample from the U.S., the incidence of PE per 100,000 was 66 in 
those with normal kidney function, 204 in CKD and 527 in ESKD.15 Using data from the 
U.S. Renal Data System and National Hospital Discharge Survey, the age-adjusted PE-
related hospitalization incidence rate ratio was 2.11 in dialysis patients compared to the 
general population.38 Similarly, in a study of National Health Insurance claims, the 
incidence rate for PE in Taiwanese dialysis patients versus age- and sex-matched controls 
was 0.92 versus 0.33 per 1000 person-years, and the adjusted HR (95% CI) for PE was 
2.0 (1.63, 2.50),39 which is similar to the increased risk in CKD. It is unknown whether 
hemodialysis poses a greater risk for VTE than peritoneal dialysis.8,39 Importantly, PE in 
dialysis patients is associated with a high mortality rate. In a study comparing European 
dialysis patients to the general population, it was reported that the age and sex 
standardized mortality rate (SMR) for PE was 12 times higher in dialysis versus the 
general population. This exceeds the SMR for myocardial infarction or stroke, which was 
11 and 8 times higher in dialysis patients versus the general population.40 The Nationwide 
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Inpatient Sample study reported in-hospital mortality associated with PE was 50% greater 
for CKD and 90% greater for ESKD compared to patients with normal kidney function.15 
The cause of ESKD is also related to the risk of mortality associated with PE in dialysis 
patients, with diabetes posing a greater risk than polycystic kidney disease.40 
 
Kidney transplantation and VTE 
There is an increased risk of VTE in kidney transplant patients as well and this is 
related to the time since transplantation.41 As compared to patients with eGFR>30 
ml/min/1.73m2, those with eGFR<30 have a 2-fold increased risk of VTE 1.5-3 years 
after transplantation.42 The immediate risk of symptomatic VTE within 90 days of 
transplant was 0.9% in a retrospective study of 441 consecutive kidney transplants from 
Argentina,43 similar to the risk associated with relatively low risk surgeries. A Korean 
study reported a 4% incidence of VTE within 90 days by screening for VTE with duplex 
ultrasound, however only one patient was symptomatic.44 An Italian study of 538 kidney 
transplant patients reported that 9% developed VTE with a median follow-up time of 17 
months, and 40% were symptomatic.41 A larger, retrospective study of healthcare data 
from Ontario, Canada studied 4,343 kidney transplant patients compared to 17,372 
matched controls from the general population. The incidence rate of VTE in kidney 
transplants was 7-fold greater than the general population but varied based on time since 
transplant. The incidence rate of VTE was greatest in the first three months post-
transplant, and while it declined over time it remained higher than the matched cohort. 
Similar to patients with ESKD, VTE in kidney transplant patients confers significant 
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morbidity and mortality. Those who experience a post-transplant VTE had a four-fold 
higher risk of death and a two-fold increased risk of death-censored graft loss compared 
to matched recipients without VTE.45 Since kidney transplant patients with VTE were 
more likely to have coronary heart disease, diabetes, peripheral vascular disease and 
recent cancer than patients without VTE, and given that the median time to death and 
death-censored graft loss was 1.8 years and 1.4 years, respectively, it seems likely that 
death and graft loss were related to underlying disease rather than the VTE itself.  
 
1.4. Mechanisms of Venous Thromboembolism in Chronic Kidney Disease 
There is a myriad of risk factors for VTE, including older age, obesity, prior VTE, 
active cancer, immobilization, recent hospitalization, surgery, or trauma, and 
thrombophilia. Studies documenting associations of biomarkers with VTE risk, reveal the 
importance of inflammation and procoagulation in the development of VTE. For 
instance, higher D-dimer,46 FVIII47 and C-reactive protein26 are independently associated 
with VTE risk. Similar directional changes in these biomarkers are seen in CKD,48,49 and 
could be mediators for VTE in people with CKD. As previously noted, two recent studies 
implicated FVIII as a potential mediator in the relationship of CKD and VTE.29,30 In the 
MEGA and REGARDS studies, FVIII attenuated 100% of the relationship of CKD and 
VTE. In comparison, reduced anticoagulant levels such as protein C, protein S and 
antithrombin did not explain VTE risk in CKD in the MEGA study, and inflammation 
had a more minor role than FVIII in the REGARDS study.29,30 Other potential 
mechanisms for VTE in CKD, such as greater platelet activation or decreased fibrinolytic 
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activity, have not been studied (Figure 1.1.). Given that FVIII appears to mediate the 
association of CKD and VTE, further study of the relationship between FVIII and CKD 
is warranted.  
Conceptually, there are at least three potential ways in which FVIII and CKD may 
be related. FVIII may represent a manifestation of kidney disease itself, it may promote 
kidney disease progression and/or it may be elevated due to the consequences of CKD 
(Figure 1.2.). To explore this further, the remainder of this review will focus on the 
biochemistry of FVIII as this may be influenced by complications of CKD, the 
determinants of FVIII and what is known about shared determinants with CKD, and the 
epidemiology of FVIII and CKD.  
 
1.5. Biochemistry of Factor VIII 
Structure 
The FVIII gene is located on the X chromosome and encodes a large precursor 
protein of 2,351 amino acids.50 FVIII is predominantly synthesized in the hepatic 
sinusoidal cells although the natural cell type that produces FVIII has not been identified 
and there are no known natural established cell lines that express FVIII.51 It is also 
believed to be synthesized by glomerular endothelial cells based on data locating FVIII 
mRNA in the kidney.52-54 The organizational structure of FVIII consists of six domains: 
A1-A2-B-A3-C1-C2.55 In the Golgi compartment, FVIII is cleaved at two sites in the B 
domain to produce the heavy (A1-A2-B) and light (A3-C1-C2) chains. It is then secreted 
as a heterodimer with a molecular weight of approximately 280 kDa. The three A 
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domains are involved in protein-protein interactions, the B domain is removed by 
thrombin activation and the two C domains are involved in phospholipid binding. Both 
chains of this heterodimer contribute to the interaction with lipoprotein receptor-related 
protein (LRP-1), a cell surface endocytic receptor expressed on a variety of human tissues 
including monocytes, fibroblasts and smooth muscle cells and is involved in FVIII 
clearance.56  The mature factor has 2,332 amino acids and circulates in plasma at a 
concentration of 0.7 nM.57 FVIII contains one calcium and two copper binding sites, and 
ion binding interactions may be important for both the structure and function of FVIII. 
FVIII is heavily glycosylated, which is also important for its structure and function.58  
 
Regulation by vWF 
After FVIII is secreted by exocytosis and once in the plasma, it is stabilized by 
non-covalent association with von Willebrand factor (vWF). This increases the half-life 
of vWF-bound FVIII to about 10 hours59 by preventing inactivation by activated protein 
C, FIXa and FXa.60,61 Deficiency of vWF-FVIII binding, as in von Willebrand disease 
type 2N, results in a secondary FVIII deficiency, due to more efficient clearance from the 
circulation.  
 
FVIII activation, inactivation and clearance 
FVIII is activated by thrombin through proteolytic cleavage at three sites. This 
results in polypeptides A1 (50 kDa), A2 (43 kDa) and A3-C1-C2 (73 kDa). When A3 is 
cleaved, FVIII dissociates from vWF and a heterotrimeric FVIIIa forms. The A1 subunit 
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derived from the heavy chain exists in a stable association with the light chain-derived 
A3-C1-C2, which is weakly associated with the A2 subunit.62 In the presence of 
phospholipids and calcium, activated FVIII (FVIIIa) forms a membrane-bound complex 
with FIXa called the FXase complex.63,64 This complex then acts to convert FX to FXa, a 
process that is amplified 100,000-fold by the presence of FVIIIa.65,66 FXa and its co-
factor FVa form the prothrombinase complex, which activates prothrombin to thrombin. 
Thrombin in turn catalyzes the conversion of soluble fibrinogen into fibrin. 
FVIII is inactivated by two mechanisms. First, the A2 subunit spontaneously 
dissociates when FVIII is activated, with a half-life of 2 minutes. Second, FVIIIa 
undergoes proteolysis by activated protein C at two sites.67 The mechanisms for FVIII 
clearance are not yet well characterized but several potential mechanisms have been 
reported.68 Free FVIII is removed from circulation primarily in the liver by binding to 
LDL-receptors, heparan sulphate proteoglycans (HSPGs), asialoglycoprotein receptors 
and megalin.69 LRP-1 mediates cellular uptake and degradation of free FVIII57,70 through 
interaction with the C2 and A2 domains, and is generally inhibited when FVIII is bound 
to vWF with few exceptions.69,71 In mouse models, LRP-1-deficient mice have higher 
plasma FVIII levels,72 and blocking both LRP and HSPGs results in prolongation of the 
FVIII half-life.71 Stabilin-2, expressed on liver endothelial sinusoidal cells, is also 
involved in vWF dependent endocytosis of FVIII.68 Both FVIII and vWF are rapidly 
degraded when they are bound by macrophages.73 Given the molecular weight of FVIII, 
it could not be renally cleared by filtration in its intact form. In summary, FVIII is 
synthesized in endothelial cells primarily in the liver, activated upon endothelial injury, 
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inactivated spontaneously and by proteolysis and cleared by the reticuloendothelial 
system in the liver. 
Studies to support direct relationships between the complications of CKD and the 
biochemistry of FVIII are lacking. Nevertheless, CKD may play a role in activation, 
inactivation or non-renal clearance indirectly by affecting enzymatic reactions, LRP-1 or 
immune function more generally. For example, metabolic acidosis is a common 
complication of CKD and the pH of the blood is important for regulating protein 
function. The dissociation of the A2 subunit of FVIIIa heavy chain is pH dependent in 
vitro,62,74 such that at lower pH there is less dissociation and greater FVIIIa activity.62,74 
Immune function is impaired in patients with CKD75 and more specifically, the uremic 
toxin, P-cresyl sulfate, suppresses macrophage function.76 Since macrophage activity is 
responsible for clearance of FVIII, CKD might lead to reduced FVIII clearance through 
reduced activity of the reticuloendothelial system.75 The inflammatory cytokines 
prominent in CKD, including TNF-alpha77 and IL-6,78 are also considered the main 
mediators of inflammation-induced activation of the hemostatic system.79,80 Elevated 
TNF-alpha mediates downregulation of protein C,81 the anticoagulant that inactivates 
FVIII. Thus, higher levels of TNF-alpha in CKD may result in less inactivation of FVIII 
and greater FVIII activity. IL-6 promotes transcription activation of FVIII,82 and in this 
way CKD related IL-6 could lead to higher FVIII levels.  
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Determinants of FVIII blood levels 
vWF is an important determinant of plasma FVIII levels. vWF is synthesized in 
endothelial cells and megakaryocytes as a pre-pro-polypeptide monomer of 2,813 amino 
acids. Each monomer contains N- and O- glycosylation sites, which are involved in vWF 
secretion and clearance.83 In endothelial cells, vWF is constitutively secreted mostly as 
dimers, and is stored as larger multimers in Weibel-Palade bodies. In platelets, vWF is 
stored in alpha-granules until platelets are activated.84  vWF multimers in the circulation 
are long filamentous strands that are loosely coiled until activation causes them to 
unwind and expose sites for platelet adhesion. There are two forms of vWF. High 
molecular weight vWF functions to promote hemostasis through facilitating platelet-
platelet interactions and platelet-subendothelium adhesion, as well as platelet 
aggregation. Low molecular weight vWF functions to carry and protect FVIII from 
activated protein C mediated proteolytic degradation or early activation by thrombin. The 
vWF binding sites are located on the A3 domain of the light chain of FVIII. Interestingly, 
there is reciprocal regulation; Factor VIII serves as a cofactor to ADAMTS13, a 
metalloprotease that proteolytically cleaves large vWF multimers.85  
ABO blood group, a genetic trait, is also a determinant of plasma FVIII levels, 
primarily through ABO blood group effect on vWF. Twin studies indicate that 
approximately 66% of the variation in plasma vWF is genetically determined, of which 
30% is explained by ABO group.86 The ABO antigens are carbohydrate molecules 
expressed on RBC membranes and other cells including epithelium, platelets and 
vascular endothelium. N-linked sugars on vWF also contain ABO blood group 
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determinants. Persons with blood group types A, B and AB (the non-O blood types) have 
higher vWF and FVIII levels. The level of vWF increases across blood types: 
O<A<B<AB. The level of FVIII also increases accordingly: O<A<AB<B. ABO type 
appears to affect clearance rather than synthesis or secretion of vWF.87-89 The receptor 
involved in ABO blood type facilitated clearance of vWF has not been identified. It has 
been suggested that ADAMTS13 may play a role in clearance of vWF since 
ADAMTS13-mediated proteolysis of vWF is much faster for O-blood group than non-O 
blood group.90 This is thought to be due to impaired ADAMTS13 cleavage since the A 
and B antigens are in close proximity to the ADAMTS13 cleavage site within the A2 
domain.91 An experimental model of ADAMTS13-deficient mice however, failed to 
support the role of ADAMTS13 in vWF clearance, but mice do not express ABO 
antigens.  
To understand whether FVIII and CKD might share common etiologic factors, we 
cross-referenced published reports of genetic variants associated with both FVIII and 
kidney disease. We did not identify any single nucleotide polymorphism (SNP) directly 
linked to both kidney disease and FVIII or vWF. Rather, we identified common genes 
important in kidney function or development and related to FVIII or vWF (Table 1.2.). 
Some of these findings were incongruous. For example, rs4981021 located at STAB-2, 
which encodes stabilin-2 protein, is associated with higher FVIII and lower vWF. 
Deficiency of stabilin 1 and 2 in mice causes glomerulofibrosis, albuminuria and early 
mortality. Other associations were congruous, such as a rs10102164 at SOX17, which is 
associated with FVIII and vWF. SOX17 is expressed throughout the urogenital tract and 
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mutations of which are associated with congenital anomalies of the kidney and urinary 
tract. Different SNPs at SYNGR1 are associated with lupus, lupus nephritis and higher 
vWF and FVIII. SYNGR1 encodes synaptogyrin1, which is an integral membrane protein 
involved in vesicle trafficking and exocytosis.  Genetic risk variants for kidney disease 
may influence proinflammatory pathways that affect FVIII. For instance, APOL-1 
genetic variants, which have a prevalence of 13% among African-Americans, are 
associated with a five-fold higher risk of progressive kidney disease.92,93 APOL1 encodes 
apolipoprotein 1 in macrophages, endothelial cells and epithelial cells and its expression 
is induced by inflammatory cytokines. In the ARIC study, the relationship of FVIII and 
ESKD varied by different APOL-1 risk variants. The HR (95% CI) of ESKD per IQR 
change in FVIII was 2.48 (1.39, 4.41) for African-Americans with two APOL-1 risk 
variants, 1.19 (0.92, 1.53) for African Americans with one risk variant or none, and 1.07 
(0.83, 1.38) for European-Americans.94 The authors suggest that vascular injury might be 
a common determinant that leads to inflammatory cytokines, which promotes higher 
factor FVIII and APOL1 expression. rs4845625 at IL6R was associated with CKD in 
Japanese, and is also associated with biomarkers of inflammation including IL6, TNF-
alpha and CRP, however FVIII and vWF were not tested.  
 
Measurement of FVIII 
As we describe the relationship of FVIII and CKD, a review of the means of 
measurement of FVIII is warranted. FVIII can be measured by quantifying the amount of 
antigen present or by determining its procoagulant activity. The most common way of 
  18  
 
measuring FVIII is the one-stage activity assay based on the activated partial 
thromboplastin time (aPTT).95 In this assay, the length of time it takes for a patient’s 
plasma to correct the clotting time of plasma known to be deficient in FVIII is measured. 
This is compared to a reference plasma, with a value of 100% FVIII activity. The 
patient’s FVIII activity is expressed as a percent of normal activity. The normal range in 
healthy adults is 50-150%. This one-stage activity assay is used clinically to detect factor 
deficiencies so the ability to detect low levels of FVIII are critical. However, given that 
our interest in distinguishing higher levels of FVIII that might be associated with 
increased thrombotic risk, the choice of an assay should address the ability to detect 
modestly elevated values. Different methods were compared using samples with high 
FVIII. The one-stage activity assay, the chromogenic activity assays and immunoassays 
had similar intra-assay precision (CV 6-8%). Inter-assay precision was best with the 
chromogenic assay (CV 13%) compared to the one-stage activity assay (CV 21.9%) and 
the ELISA (CV 19.3%).95 The one-stage assay was affected by lepirudin, lupus 
inhibitors, low-molecular weight heparin and unfractionated heparin; while the 
chromogenic assay and immunoassay were unaffected by these factors. The majority of 
studies relating FVIII and CKD measure FVIII activity. Of note, Factor VIII measured by 
one-stage activity assay was highly correlated with FVIII measured by a two-stage 
ELISA, r= 0.87.96 Biological variation of FVIII has been examined in short and long-
terms studies. Within individual variation was 4.8-11.4% (for repeated measures within a 
week) and 15.8% (for repeated measures monthly across a year).97-99 There was no 
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apparent difference in the mean values for FVIII activity throughout the day to suggest 
that there is a circadian pattern to FVIII.98  
 
1.6. Association of Factor VIII and Chronic Kidney Disease 
Epidemiological studies of FVIII, vWF and CKD  
Several cohort studies support an association of FVIII and kidney disease (Table 
1.3.). In CHS, renal insufficiency, which was defined as a serum creatinine 1.3 mg/dL in 
women and 1.5 mg/dL in men, was associated with higher mean (± SEM) FVIII (145 ± 
2%) compared to those without renal insufficiency (131 ± 2%), among 5,888 older 
adults.49 Using a more contemporary measure of kidney function, the Multiethnic Study 
of Atherosclerosis (MESA) studied 6,751 self-identified Caucasian, Chinese, African-
American and Hispanic participants who were free of cardiovascular disease at the time 
of study enrollment and had relatively preserved kidney function (mean eGFR 
79ml/min/1.73m2).100 Factor VIII was inversely associated with eGFR; for every 10 
ml/min/1.73m2 decrement in eGFR, FVIII was 2% (95% CI 1, 3) higher and vWF was 
3% (95% CI 1, 5) higher. The British Regional Heart Study included 4,029 men age 40-
59 recruited from 1998-2000 with eGFR 15  70 ml/min/1.73m2.101 FVIII increased 
across eGFR categories; median (IQR) FVIII was 131 (130, 133)% for eGFR  70, 132 
(130, 133)% for eGFR 60-69, and 135 (133, 138)% for <60 ml/min/1.73m2, p-trend 
<0.001. Two prospective cohort studies reported an association of baseline FVIII and 
CKD risk. The ARIC study of 14,854 participants, demonstrated higher vWF and FVIII 
in participants with CKD compared to those without CKD.102 In this study, the HR (95% 
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CI) for incident CKD over a mean follow-up time of 14.5 years in the highest versus the 
lowest quartile was 1.46 (1.26, 1.68) for vWF and 1.39 (1.20, 1.60) for FVIII. In MESA, 
FVIII was also associated with rapid kidney function decline (defined as eGFR decline 
>3 ml/min/year); the OR (95% CI) of rapid decline was 1.11 (1.03, 1.18) per standard 
deviation (SD) higher FVIII.48 In summary, across a wide spectrum of ages above 40 
years, mild to moderate kidney disease was associated with higher levels of FVIII, and 
higher FVIII was also linked to progression of CKD.   
 
Studies of FVIII, vWF and end-stage kidney disease 
The association of FVIII and kidney disease has also been reported in ESKD and 
in patients receiving maintenance dialysis, albeit in small studies and without adjustment 
for covariates.103 Among 21 patients with kidney failure and 42 with kidney failure on 
established hemodialysis, FVIII and vWF were 2-3-fold higher than normal adult 
controls.104 Mean (± SD) FVIII was 233 ± 123% in kidney failure, 218 ± 10% in dialysis 
and 79 ± 27% in controls and vWF was 247 ± 154% in kidney failure, 265 ± 159% in 
dialysis and 94 ± 31% in controls.104  In an early study that compared FVIII in 38 patients 
with kidney failure, 19 hospitalized patients with normal kidney function and 17 normal 
subjects, FVIII was elevated in both patient groups, and mean FVIII was significantly 
higher in those receiving dialysis versus non-dialytic (conservative) treatment.105  Not all 
reports agreed with these findings; in a study of 57 patients with kidney failure, 49 
patients with normal kidney function and 8 with impaired kidney function, the authors 
failed to find a correlation between vWF and FVIII and kidney function.106 Given the 
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individual variability in FVIII, a comparison of FVIII in the same patients before and 
after dialysis might clarify if commencing maintenance dialysis is associated with lower 
FVIII. In 16 patients with chronic kidney failure who later started dialysis, mean (± SEM) 
FVIII was significantly lower after being established on dialysis: FVIII was 279 ± 36% in 
chronic kidney failure versus 218 ± 28% in established dialysis, p <0.05. Mean vWF was 
not significantly different.104 A more recent study reported FVIII and vWF were elevated 
prior to starting dialysis and by six months mean FVIII and vWF were greatly reduced.107 
The hemodialysis procedure may affect FVIII differently than vWF. In ten patients 
studied immediately before and after receiving dialysis, FVIII increased in some and 
decreased in others, while vWF levels were increased following dialysis.103 vWF also 
increases with duration of the dialysis procedure.104 As endothelial cells release both 
vWF and FVIII, whereas platelets release vWF but not FVIII, increased vWF in dialysis 
may be due to platelet activation as the blood comes in contact with the extracorporeal 
circuit in hemodialysis. There are fewer studies in peritoneal dialysis, but they support a 
similar pattern. Among 14 patients receiving continuous ambulatory peritoneal dialysis 
Factor VIII and vWF were significantly greater (301 ± 122% and 372 ± 112%, 
respectively) than in ten normal controls (101 ± 11%, and 99 ± 7%, respectively).108 
Small studies of kidney transplant recipients indicate that FVIII109 and vWF levels 
are elevated in the early post-transplant period.103 As in the studies of FVIII and vWF in 
dialysis patients, there was no adjustment for covariates. In a study of 17 consecutive 
deceased donor kidney transplant recipients on cyclosporine immunosuppression, pre-
transplant FVIII activity was 224%, FVIII antigen was 248% and vWF was 206%. These 
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measures increased transiently to 360% for FVIII activity, 398% for FVIII antigen and 
362% for vWF. By four months post-transplant they returned to pre-transplant levels.110 
Similar findings were reported in eight kidney transplant patients before and 4 weeks post 
transplantation.109 Another small study of 11 patients with functioning kidney transplants, 
the reported mean FVIII (± SD) was 179 ±100 and vWF (±SD) was 136 ±64 six months 
to 6 years post-transplant. These values were similar to FVIII and vWF in hemodialysis 
patients.103 Despite presumed restoration of kidney function, FVIII levels are not returned 
to a normal range, perhaps due to immunosuppressive agents related prothrombotic 
effects or endothelial damage. 
 
Epidemiology of FVIII, vWF and albuminuria or proteinuria 
Albuminuria, which is a marker of endothelial dysfunction111 as well as kidney 
disease, is associated with elevated levels of FVIII and vWF. In an early study of 57 
patients with diverse forms of kidney disease, vWF and FVIII were positively correlated 
with magnitude of proteinuria.106 These findings were confirmed in two other 
studies,112,113 and this relationship between higher ACR and higher vWF levels, vWF 
activity and FVIII persisted after adjustment for risk factors.113 Among type 1 diabetics, 
vWF was elevated in those with albuminuria (ACR  30 mg/g) and/or reduced GFR 
(eGFR<60 ml/min/1.73m2) as compared to those without albuminuria.114 For every 88.5 
mg/g increase in UACR, the vWF and FVIII levels were 8.3% and 6.3% higher. In 
nephrotic syndrome where proteinuria exceeds 3.5 grams per day, vWF was much higher 
(287 ± 26%) than in controls (99 ± 5%), and this was independent of presence of chronic 
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renal failure.115 The relationship between FVIII and albuminuria may differ by 
race/ethnicity. In a study of 1,051 self-identified, African-Americans and 894 non-
Hispanic whites with hypertension, albuminuria was associated with higher FVIII and 
vWF in African-Americans, but not in non-Hispanic whites.116  
 
FVIII and vWF in different etiologies of CKD  
If there were distinct patterns of FVIII in different etiologies of kidney disease, 
independent of kidney function, this might indicate that FVIII elevation in kidney disease 
represents the underlying pathology of the kidney disease. There are only a few studies 
that address the relationship of kidney disease etiology and FVIII or vWF. The studies 
are limited by small sample size and lack of control for eGFR, albuminuria and other 
important covariates. In one study of 105 patients, vWF was higher in minimal change 
disease compared to membranous nephropathy or focal segmental glomerulonephritis 
among primary renal disorders, and vWF was higher in lupus and amyloid compared to 
Alport’s syndrome or mixed cryoglobulinemia among secondary causes of 
glomerulonephritis.112 A second study confirmed that vWF was higher in nephrotic 
syndrome, and noted it was also higher in lupus nephritis and hypertensive nephropathy 
compared to diabetic nephropathy and chronic glomerulonephritis,117 but a third study 
reported vWF was higher in lupus nephritis compared to nephrotic syndrome.118 Among 
non-insulin dependent diabetic patients, there is a heterogenous relationship of vWF to 
albuminuria, which is dependent on the kidney pathology.119 Patients with typical 
diabetic nephropathy changes had higher levels of vWF compared to those with more 
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atypical biopsy findings, such as advanced tubulointerstitial fibrosis. This study supports 
the concept that the underlying kidney pathology is related to vWF. The data exploring 
the etiology of kidney disease in relation to FVIII in dialysis patients is conflicting. In 
one study, Factor VIII levels did not differ between non-diabetic and diabetic 
hemodialysis patients, although FVIII activity was twice that of healthy controls.120 In a 
more recent study of 37 CAPD patients, mean (± SE) FVIII and vWF were significantly 
higher in diabetics (195 ± 4% and 169 ± 5%) compared to non-diabetics (159 ± 5% and 
124 ± 9%).121 Larger studies are needed to determine whether kidney disease etiology 
influences FVIII.  
 
ADAMTS13 and CKD 
There is growing evidence to support a relationship between ADAMTS13 and 
CKD etiology as well as kidney function. Among type 1 diabetics, kidney function was 
positively correlated with ADAMTS13 antigen and activity; ADAMTS13 activity was 95 
± 16% in controls, 104 ± 20% in mild CKD, and 108 ± 19% in severe CKD.122 
ADAMTS13 levels are also reduced in dialysis patients compared to controls; median 
(IQR) ADAMTS13 was 279 (238-329) ng/mL in HD patients and was 578 (486-690) 
ng/mL in controls.123  vWF levels are elevated and ADAMTS13 levels are reduced in a 
variety of etiologies of CKD including lupus nephritis, nephrotic syndrome, diabetic 
nephropathy and chronic glomerulonephritis compared to normal controls.118,124 In 
acquired or genetic deficiency of ADAMTS13, ultra-large multimers of vWF accumulate 
resulting in platelet aggregation and microthrombi. This clinical syndrome known as 
  25  
 
thrombotic thrombocytopenia purpura (TTP) can be life-threatening and not uncommonly 
causes acute kidney failure. It is not known outside of TTP if lower levels of 
ADAMTS13 cause CKD, although one study reported that higher vWF:ADAMTS13 
ratio is associated with a decline in kidney function.125  
 
Prospective studies of ABO, FVIII and CKD 
There is growing evidence linking ABO blood group to cardiovascular diseases. 
For instance, in a US study the risk of stroke was increased in blood type AB, 
independent of FVIII and typical stroke risk factors.126 In the same cohort, blood type AB 
was also associated with incident cognitive impairment , with only part of the association 
attenuated by FVIII.127 There is considerable data linking non-O blood groups and risk of 
coronary artery disease128 and VTE.129-132 Non-O blood type is associated not only with 
higher levels of vWF and FVIII but also several inflammatory cytokines that are related 
also to VTE risk, including sICAM-1,133 IL6, TNF-alpha, e-selectin134,135 and p-
selectin.133,135 Thus ABO blood type may have an effect on VTE independent of vWF 
and FVIII. 
The literature on ABO blood type as it relates to CKD is scarce. A few small 
studies compare the prevalence of ABO blood groups in CKD and ESKD using healthy 
donors as a comparison group (Table 1.4.).  None of the published reports account for 
FVIII. In the US, veteran patients with CKD had blood group B more frequently and 
blood group O less frequently than healthy controls.136 In a German study of different 
etiologies of CKD, Blood group A was more prevalent among females with 
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pyelonephritis, than blood type O, but there were no differences among males.137 A cross-
sectional study of 195 Brazilian hemodialysis patients and 80 healthy subjects, 
demonstrated no significant differences in ABO blood group distribution between 
patients and controls.123 In 231 Syrian hemodialysis patients, Blood group B was more 
common and A was less common in dialysis patients than blood donors.138 The sum of 
the literature suggests that B and AB are more common and O and A are less common in 
dialysis patients, but larger prospective studies are necessary to confirm the possible 
relationship between ABO blood group and kidney disease.  
 
Hemophilia and kidney function 
Several lines of evidence report that hemophilia might be protective against CKD. 
Hemophilia A is an X-linked disorder caused by mutations in the FVIII gene and results 
in low or absent FVIII. Given that higher FVIII is related to kidney disease, lower FVIII 
might be associated with less kidney disease. Two cross-sectional studies showed that 
people with severe hemophilia had higher kidney function than those with mild or 
moderate hemophilia.139,140 In a study of 532 hemophiliacs, the reported prevalence of 
CKD was 5.5%, which is less than the prevalence of CKD in the general US population. 
The study sample had a median age 52 (range 40-98), but there was no comparison group 
and CKD prevalence rates were not reported separately for Hemophilia A and B.140 A 
third study of 3,422 hospitalized hemophilia patients (79% Hemophilia A) found that 
CKD was a discharge diagnosis in just 31 patients. There was no association between 
CKD and severity of hemophilia; the OR of CKD with severe versus mild/moderate 
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hemophilia was 0.7 (95%CI 0.3-1.7), after multivariable adjustment.141 While these 
studies suggest that hemophilia may be associated with better kidney function, they are 
not conclusive. 
 
1.7. Research gaps and future directions 
While there is data to support a relationship of CKD and FVIII several questions 
remain. First, is FVIII elevated due to consequences of CKD or does FVIII cause CKD? 
Studies that describe this association are for the most part limited to a single 
measurement of FVIII and kidney function, which limits our understanding of how FVIII 
might influence kidney function and vice-versa. Second, are different etiologies of CKD 
associated with different levels of FVIII? Studies addressing this issue are small, present 
conflicting results and do not control for important covariates or kidney function. 
Identifying the etiology of CKD is not straightforward, however, as biopsies are not 
performed routinely and are not always conclusive. Accumulating sufficient biopsy-
proven cases to compare FVIII levels across a range of CKD etiologies would be 
difficult. Third, do CKD and FVIII share similar genetic predisposition, including but not 
limited to the potential impact of ABO blood type? Finally, as FVIII appears to mediate 
the association of CKD and VTE, could efforts to lower FVIII reduce the risk of VTE? 
Future research should aim to characterize the mechanisms of elevated FVIII 
activity in CKD and assess the directionality of the relationship of FVIII and CKD, 
including evaluation of potential confounders and common predictors. For instance, ABO 
blood type might lead to CKD in addition to its impact on FVIII levels, but this has not 
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yet been studied prospectively. A focus on macrophage clearance of FVIII in CKD versus 
non-CKD might help elucidate if immune function is critical to this relationship. 
Investigations on the impact of specific uremic toxins, such a P-cresyl sulfate, on 
coagulation and inflammatory pathways, including effect on proteins critical for 
coagulation, are currently lacking.  
 
1.8. Conclusions 
CKD is an emerging risk factor for venous thromboembolism. The mechanisms of 
the association of kidney disease and VTE are understudied, but new evidence supports 
FVIII as a mediator. FVIII activity is inversely correlated with kidney function from mild 
to severe kidney disease, and remains high in dialysis and kidney transplantation. vWF 
and ABO blood group are recognized determinants of FVIII, and are also linked to CKD. 
A greater understanding of the pathophysiological mechanisms for higher FVIII in CKD 
is necessary, and could lead to discoveries that would improve FVIII levels and reduce 
VTE in CKD. 
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Table 1.1.: Case-control and cohort studies of Chronic Kidney Disease and Venous Thromboembolism 
Country, 
Recruitment 
period 
Study design, 
name 
N participants Patient 
characteristics 
Measure of 
kidney disease 
Findings HR or OR (95% CI) 
Netherlands 
1994-1995 
Cohort, Tromso32 3,251 Age 25-84 Cystatin C  HR 2.5 (1.27, 4.96) for top vs bottom quartile of 
cystatin C 
USA 
1987-1989 
Cohort, ARIC33 10,700 Age 53-75; 
White (n=8,317) and 
African-American 
(n=2353) 
Cystatin C based 
eGFR 
HR 1.40 for eGFR 60-89, 1.94 for eGFR 15-59 
compared to eGFR >90 ml/min/1.73m2 
No association of creatinine based eGFR and VTE 
USA Cohort, LITE6 19,073 Mean age 59 yrs; 
75% white 
Creatinine-based  
Cystatin C 
HRs 1.29 (1.02, 1.62) for eGFR 60-89 and 1.71 
(1.18, 2.49) for eGFR 15-59 compared to eGFR90 
ml/min/1.73m2 
No association of cystatin C and VTE 
USA 
2003-2007 
Cohort, 
REGARDS7 
30,239 Age 45 and older; 
46% male; 60% 
white, 40% black 
Creatinine-cystatin 
C based 
ACR 
HRs 1.28 (0.94, 1.76) for eGFR 60-90, 1.30 (0.77, 
2.18) for eGFR 45-60 and 2.13 (1.21, 3.76) for 
eGFR <45, compared to eGFR 90 ml/min/1.73m2.   
No association of ACR w VTE 
Netherlands 
1999-2004 
Case-control, 
MEGA29 
2936 controls, 
2473 cases 
Age 18-70; cases 
46% male 
Creatinine-based 
eGFR  
OR 1.2 (1.0, 1.4) for eGFR 60-90, 2.2 (1.5, 3.0) for 
eGFR <>90 ml/min/1.73m2 
Denmark 
1980-2010 
Case-control35 128,096 cases, 
624,426 
controls 
Hospitalized 
patients; cases 47% 
male 
Creatinine-based 
eGFR (MDRD) 
OR 1.27 (1.10, 1.47) for hypertensive nephropathy 
and 2.17 (1.68, 2.80) for nephrotic syndrome 
compared to healthy controls 
Europe & 
USA 
Meta-analysis,4 
Tromso, ARIC, 
CHS, HUNT2, 
PREVEND 
1,178 events, 
95,154 
participants 
97% white, 47% 
male across 5 studies 
Creatinine-based 
eGFR 
 
 
ACR  
HRs 1.29 (1.04, 1.59) for eGFR 75), 1.31 (1.00, 
1.71) for eGFR 60, 1.82 (1.27, 2.60) for eGFR 45, 
1.95 (1.26, 3.01) for eGFR 30, compared to eGFR 
100 ml/min/1.73m2. 
HRs were 1.34 (1.04, 1.72) for ACR 30, 1.60 (1.08, 
2.36) for ACR 300 and 1.92 (1.19, 3.09) for ACR 
1000 mg/g, compared to ACR 5.0 mg/g. 
Netherlands Cohort, 
PREVEND5 
40,856 99% white; 50% 
male 
ACR HR2.0 for ACR 30-300mg/g compared to ACR <30 
mg/g 
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Table 1.2.: Genes and SNPs associated with Factor VIII and vWF and Kidney Disease 
Gene Protein function Association with FVIII or vWF Association with Kidney disease 
APOL1 
 
Apolipoprotein L1 is a minor apoprotein of 
HDL with a role in innate immunity 
(trypanolytic factor) and possibly the 
inflammatory response. 
FVIII is associated with ESKD and 
APOL1 risk alleles modify this 
association. If both APOL1 risk alleles are 
present, FVIII is associated with two-fold 
risk of ESKD, but is only one risk allele or 
none are present FVIII is not associated 
with ESKD.94 
APOL1 risk alleles (rs73885319 and 
rs60910145 are referred to as G1 and in perfect 
linkage disequilibium; rs71785313 is referred 
to as G2) are associated with seven-fold 
increased risk ESKD in blacks G1 p=1.1 x 10-
39 and G2 p=8.8 x 10-18 if both risk alleles are 
present compared to none.93 
SOX17 SOX17 is a transcription factor essential for 
endothelial cell morphogenesis, necessary 
for function of stable endothelial cells,142 
expressed throughout urogenital tract and 
regulates beta-catenin signaling. SOX17 is 
also a potent Wnt-signaling antagonist.143 
rs10102164 is associated with FVIII p=2.4 
x 10-9 and vWF p=2.9 x10-3. 144 It is 
unknown how SOX17 might regulate 
FVIII or vWF. 
SOX17 mutations are associated with 
duplication of urinary tract, vesico-ureteric 
reflux, is associated with congenital anomalies 
of kidney and urinary tract (CAKUT).143 
TMEM171 Transmembrane protein that is associated 
with urate levels. 
rs548630 is associated with vWF 
p=1.2x10-10 and FVIII p= 2.1 x 10-10.145 
TMEM171 in regulating vWF and FVIII is 
unknown, but it is associated with higher 
basal vWF and secretion of vWF under 
stimulus. 
Rs17632159 is associated with serum urate 
levels p=3.5 x 10-11 and gout OR 0.91 p=6 x10-
3. 146 rs17632159 is associated with systolic 
and diastolic BP.147 
Frequency A1 0.31. effect for serum urate -
0.039. 
STAB-2 
 
Stabilin 2 protein, large transmembrane 
receptor protein with potential functions in 
angiogenesis, receptor scavenging, cell 
adhesion, lymphocyte homing, endocytosis 
of AGE modified proteins 
rs4981021 is associated with FVIII, p=3 
x10-20 and vWF p=6 x 10-41.145 
rs4981021 serves as proxy for rs12229292 
(r2 = 0.879) and is associated with higher 
FVIII and lower vWF.144 
Deficiency of Stabilin 1 and 2 in mice causes 
glomerulofibrosis, albuminuria and early 
mortality.148  
No GWAS linking specific SNPs to kidney 
disease. 
SYNGR1 
 
Synaptogyrin1 integral membrane protein 
associated with presynaptic vesicles in 
neuronal cells and may have a role in vesicle 
trafficking, synaptic machinery and 
exocytosis. 
rs5750823 is associated with FVIII p=1.5 
x10-6 and vWF p= 6 x10-14.145 SYNGR1 is 
associated with higher basal vWF. 
rs61616683 is associated with lupus in East 
Asians Pmeta 5.73 x 10-10 and lupus nephritis in 
Chinese149,150  
Interleukin 
6 receptor 
(IL6R) 
 
IL6 promotes transcription of FVIII and 
regulates inflammation 
rs 4845625 (in full linkage disequilibrium 
with rs6689393) and other variants in 
IL6R are associated with biomarkers of 
inflammation including C-reactive protein, 
fibrinogen, soluble IL6R, IL6, IL8, TNF-
rs4845625 identified as candidate gene given 
association of CAD in GWAS in whites, was 
significantly related to CKD in cross-sectional 
study of 2247 Japanese (1,588 of whom had 
CKD defined as eGFR<60 ml/min/1.73m2).152  
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alpha.151 
RAB27A 
STXBP5 
Rab GTPases regulate intracellular 
membrane traffic.153 Rab27A is recruited to 
weibel-palade bodies, where vWF is stored 
in endothelial cells. Rab27a and its effector 
slp4-a regulate apical transport of Rab27 
bearing vesicles in polarized renal epithelial 
cells and control cell size.154 
Rab27a regulates vWF release from 
endothelial cells. STXBP5 promotes 
weibel-palade body exocytosis by 
interaction with Rab27a effector 
slp4a.155Silencing STXBP5 impairs vWF 
secretion. rs9390459 (near STXBP5) is 
associated with higher vWF and FVIII.144  
rs1528472 (near RAB27a) is associated with 
proteinuria in adults, p=5 x 10-7. 156 
PLA2R1 
 
PLA2R is a type 1 transmembrane receptor 
that binds and removes secreted PLA2 
enzyme from circulation. PLA2 is 
proinflammatory.  
sPLA2-IIA correlates with FVIII and 
vWF157 but there are no identified 
PLA2R1 SNPs associated with FVIII and 
vWF. 
rs17830558, PLA2R1, OR = 2.2, P =1.9 × 10-
8.158 The gene encoding PLA2R is expressed in 
podocytes and is the target of auto-antibodies 
responsible for ~70% idiopathic membranous 
nephropathy, a type of nephrotic syndrome.159 
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Table 1.3.: Cross-sectional and Cohort studies on Factor VIII and Chronic Kidney Disease 
Study year, 
country 
Study design N patients Biomarker Findings 
2003, US 
CHS49 
Cohort study, 
cross-sectional 
analysis 
5,888 older adults 
CKD defined as SCr >-
1.3 mg/dL in women, 
1.5 mg/dL men 
FVIII activity FVIII was higher in CKD adjusting for age, sex, race, education, 
DM, HTN, SBP, DBP, triglycerides, smoking, alcohol, physical 
activity, BMI, CVD. 
2006, UK 
Cohort, British 
Regional Heart 
Study101 
Cohort study, 
cross-sectional 
analysis 
4,029 adults age 60-79  
 
FVIII activity, 
vWF Antigen 
FVIII and vWF were higher across categories of eGFR >=70, 60-70, 
<60, adjusting for age, DM, HTN, CVD, SBP, HDL, BMI, LVH, 
alcohol, smoking, physical activity. 
2009, US 
Cohort, 
ARIC102 
Cohort study, 
prospective 
analysis 
14,854 middle age adults 
from 4 different US 
communities 
FVIII activity, 
vWF Antigen 
FVIII and vWF were associated with incident CKD, adjusting for 
age, sex, race, DM, SBP, antihypertensive use, CVD, smoking, 
alcohol use, TG, HDL, LDL, baseline eGFR. 
FVIII more strongly associated with CKD among those with DM vs 
without DM (p ixn <0.01). 
2011, US 
Cohort, 
MESA100 
 
Cohort study, 
cross-sectional 
analysis 
6,751 adults free of CVD 
at entry 
Reference group: eGFR 
cystatin C >90 
ml/min/1.73m2 
FVIII activity, 
vWF Antigen 
FVIII and vWF were higher in lower eGFR, adjusting for age, sex, 
race, income, study site, smoking, alcohol, BMI, DM, HTN, statin 
use, ACE-I, LDL, HDL, TG, fasting glucose and 
ln(albumin/creatinine). 
2012, US 
Cohort, 
MESA48 
Cohort study, 
prospective 
analysis 
4,966 adults free of CVD 
at entry 
 
FVIII activity FVIII was associated with renal decline, and rapid decline, adjusting 
for age, sex, race, DM, HTN, HDL, LDL and albuminuria.  
2014, 
Netherlands 
MEGA study29 
Case-control, 
cross-sectional 
analysis 
 
2,936 controls. 
Reference group: eGFR 
>86 (50th percentile) 
FVIII activity, 
vWF antigen 
 
FVIII, vWF were higher in eGFR<1st percentile (eGFR <53) vs ref. 
FVIII and vWF were higher with lower eGFR, adjusting for age and 
sex. 
2018, US, 
REGARDS30 
Case-Cohort 
study, cross-
sectional 
949 cohort random 
sample 
FVIII antigen FVIII was higher in lower eGFR, adjusting for age, sex, race, BMI, 
DM, HTN, CVD, hyperlipidemia, and smoking. 
Abbreviations: HTN hypertension; DM diabetes; CVD cardiovascular disease, SBP systolic blood pressure; BMI body mass index; LVH left ventricular 
hypertrophy; ACE-I angiotensin converting enzyme inhibitor; LDL low density lipoprotein; HDL high density lipoprotein, TG triglycerides;  
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Table 1.4.: Distribution of ABO blood groups in hemodialysis patients and controls 
Study 
country 
N patients 
 
A B AB O Reported differences in 
frequencies among patients and 
controls 
Syria138 231 hemodialysis patients 71 (30.7) 34 (14.7) 8 (3.5) 118 (51.1) B more common in dialysis, A 
less common in dialysis 
compared to donors 
 11,320 blood donors* 4,528 (40) 906 (8) 566 (5) 5320 (47) 
US136 184 CKD patients including dialysis 75 (40.8) 27 (14.7) 6 (3.3) 76 (41.3) B more common in renal patients, 
O less common compared to 
donors 
 37 dialysis patients 12 (32.4) 9 (24.3) - 16 (43.2) 
 3,820 blood donors* 1540 (40.3) 325 (8.5) 135 (3.5) 1820 (47.6) 
Brazil123 195 hemodialysis 60 (30.8) 28 (14.3) 9 (4.6) 98 (50.3) No significant differences 
 80 healthy controls 28 (35) 8 (10) 7 (8.8) 37 (46.2) 
Jordan160 197 kidney failure 90 (45.7) 34 (17.3) 13 (6.6) 60 (30.4) No comparison group 
 No controls      
Iran161 151 hemodialysis patients 55 (34.6) 26 (17.2) 62 (41) 8 (5.3) No comparison group 
 No controls      
Iraq162 60 hemodialysis patients 6 (10) 15 (25) 6 (10) 33 (55) No comparison group 
 No controls      
Total 871 dialysis and kidney failure 
patients 
294 (33.8) 146 (16.8) 98 (11.3) 333 (38.2)  
*Number of blood donors per blood group inferred from total percentage reported. 
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Figure 1.1.: Potential mechanisms of Venous Thromboembolism in Chronic Kidney 
Disease 
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Figure 1.2.: Potential explanations for elevated Factor VIII in Chronic Kidney 
Disease 
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2.1. Abstract 
Background: Kidney disease has been associated with venous thromboembolism (VTE) 
risk, but results conflict and there is little information in blacks. 
Study design: Prospective cohort study 
Setting & participants: 30,239 black and white adults age 45 and older enrolled in the 
Reasons for Geographic and Racial Differences in Stroke (REGARDS) study between 
2003-7.  
Predictors: Estimated GFR using the combined creatinine-cystatin C (eGFRCr-CysC) 
equation and urinary albumin-creatinine ratio (ACR). 
Outcomes: The primary outcome was adjudicated VTE and secondary outcomes were 
provoked and unprovoked VTE separately. Mortality was a competing risk event.  
Results: Over 4.6 years of follow-up, 239 incident VTE events occurred over 124,624 
person-years. Cause-specific hazard ratios (HRs) of VTE were calculated using 
proportional hazards regression adjusted for age, sex, race, region of residence and body 
mass index. The adjusted VTE HRs (95% CI) for eGFRCr-CysC 60-<90, 45-<60 and <45 
versus ≥90 ml/min/1.73m2 were 1.28 (0.94, 1.76), 1.30 (0.77, 2.18) and 2.13 (1.21, 3.76). 
The adjusted VTE HRs (95% CI) for ACR 10-<30, 30-<300, >300 vs <10mg/g were 1.14 
(0.84, 1.56), 1.15 (0.79, 1.69) and 0.64 (0.25, 1.62). Associations were similar for 
provoked and unprovoked VTE.  
Limitations: Single measurement of eGFR and ACR may have led to misclassification. 
Smaller numbers of events may have limited power.  
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Conclusions: There was an independent association of low eGFR (<45 vs ≥90) with 
VTE risk, but no association of ACR and VTE.  
2.2. Introduction 
Chronic kidney disease (CKD) affects 13% of the general population1 and is a 
strong independent risk factor for death and cardiovascular disease including stroke, 
coronary disease, heart failure and peripheral arterial disease.2 There is an increased risk 
of venous thromboembolism (VTE) in nephrotic syndrome,3 in patients receiving 
maintenance dialysis,4  and in renal transplant recipients5,6 but the risk of VTE in patients 
with earlier stages of CKD is unclear.7-9 VTE consists of deep vein thrombosis (DVT) 
and pulmonary embolism (PE) and is the third leading vascular disease in the U.S., 
affecting approximately 500,000 Americans each year and contributing to >100,000 
deaths annually.10 Prior studies linking measures of kidney function and VTE conflict, 
possibly due to varying composition and limited statistical power or the use of different 
measures of kidney disease in these studies, including various equations for estimated 
glomerular filtration rate (eGFR) and definitions of albuminuria. 
To better elucidate the relationship between CKD and VTE, we assessed the 
associations of kidney disease measures with incident VTE in the Reasons for 
Geographic and Racial Differences in Stroke (REGARDS) study. We had four primary 
aims. First, to determine the association of albuminuria and eGFR, in particular eGFR 
based on combining creatinine and cystatin C (eGFRCr-CysC), and VTE in the REGARDS 
study. Second, because results of prior studies disagreed as to whether CKD is more 
strongly associated with unprovoked or provoked VTE9,11 (which refers to VTE preceded 
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within 90 days by major trauma, surgery, or marked immobility or associated with active 
cancer or chemotherapy), we evaluated associations of kidney disease measures with 
each VTE type. We hypothesized that the association would be larger for provoked than 
unprovoked VTE because persons with CKD might be more likely to be hospitalized and 
require surgery. Third, since prior studies had limited numbers of black participants, and 
CKD disproportionately affects blacks, we sought to evaluate whether race modified the 
association of CKD and VTE.  Finally, to contextualize the importance of CKD with 
regards to VTE risk, we compared the population attributable fraction for a range of 
kidney function to that of older age and obesity, which are established VTE risk factors. 
 
2.3. Methods 
Study population and design: 
We studied participants in the REGARDS study, a prospective, nationally representative 
cohort study of blacks and whites in the US, which has been previously described.12 
REGARDS enrolled 30,239 black and white men and women age 45 and older between 
2003-2007. Due to the goals of REGARDS to assess black-white disparities in stroke and 
cognitive decline, only self-identified non-Hispanic white and black individuals were 
included. Additional exclusion criteria included medical conditions preventing long-term 
participation, active cancer, active treatment for cancer, residence in or awaiting 
placement in a nursing home, or inability to communicate in English. For this analysis we 
excluded participants who had baseline VTE, were missing measures of kidney disease, 
or who reported being on dialysis.  
 51 
  
 
Participants were identified from commercially available lists of residents and 
recruited through a mailing followed by telephone contact (response rate 33%). Of 
eligible participants contacted, the cooperation rate was 49%, similar to many other 
cohort studies. Participants first completed a computer-assisted telephone interview for 
self-reported demographic, risk factor and medications data. Then they underwent an in-
home visit at which written informed consent was obtained, and anthropomorphic data, 
medication inventory, urine samples and fasting phlebotomy were performed.  During the 
in-home examination, standardized protocols were followed to obtain 2 blood pressure 
measurements that were averaged for analysis, an electrocardiogram (ECG), height and 
weight. Blood and urine samples were collected after a 10 to 12 hour fast. Blood was 
centrifuged locally, and shipped with the urine samples on ice packs to the University of 
Vermont Laboratory for Clinical and Biochemistry Research for reprocessing and 
analysis or storage.13 The study was approved by all institutional review boards at 
participating universities, University of Alabama IRB 00000726, University of Vermont 
CHRMS 00-295.   
 
Laboratory methods: 
Serum creatinine was measured using an isotope-dilution mass spectrometry–
traceable method14 using the Vitros 950IRC instrument (Johnson & Johnson Clinical 
Diagnostics, Rochester, NY), with a coefficient of variance (CV) of 1.1%.  Urinary 
albumin was measured with the BN ProSpec nephelometer (Dade Behring, Marburg, 
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Germany) with CV of 2.2% at 110 mg/L and 4.3% at 13 mg/L. Urinary creatinine was 
measured with a rate-blanked Jaffé procedure, using the Modular-P analyzer 
(Roche/Hitachi) with CV of 2.6% at 66 mg/dL and 8.6% at 156 mg/dL. Serum cystatin C 
was measured with high sensitivity particle-enhanced immunonephelometry (N Latex 
Cystatin C on the BNII, Dade Behring, Deerfield, IL), with an intra-assay CV of 2.0-
2.8% and an inter-assay CV of 2.3-3.1%. 
 
Definitions: 
eGFR was calculated using the CKD-EPI equations based on creatinine 
(eGFRCr), cystatin C (eGFRCysC) and combined creatinine-cystatin C (eGFRCr-CysC).
15 
eGFR was categorized as <45, 45-<60, 60-<90, ≥90 ml/min/1.73m2 to correspond to 
clinical categories. Urinary albumin to creatinine ratio (ACR) was categorized as <10, 
10-<30, 30-<300, ≥300 mg/g. 
Covariates of interest were obtained at baseline and included age, sex, race (self-
reported as black or white), region of residence (southeast or non-southeast), body mass 
index (BMI) in kg/m2, hypertension, diabetes, hyperlipidemia, cardiovascular disease 
(CVD), smoking, self-report of current postmenopausal hormone therapy (HT), aspirin 
(ASA), statin or warfarin use. Hypertension is deﬁned as systolic blood pressure >140 
mm Hg and/or diastolic blood pressure >90 mm Hg and/or use of antihypertensive 
medication. Diabetes is deﬁned as fasting glucose >126 mg/dL, non-fasting glucose >200 
mg/dL, or use of diabetes medication. Hyperlipidemia was defined as cholesterol >240 
mg/dL or low density lipoprotein >160 mg/dL or taking medications for high cholesterol. 
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CVD was defined as a self-report of pre-baseline myocardial infarction, aortic aneurysm, 
stent, coronary artery surgery or stroke. 
 
Identification and validation of outcomes: 
 The primary outcome was incident VTE, ascertained as previously described.16 
In brief, medical records were obtained from potential VTE events, each of which was 
reviewed by two physicians and major disagreements settled by a blinded third 
reviewer.16 Provoked VTE was defined as a VTE that was preceded within 90 days by 
major trauma, surgery, or marked immobility or associated with active cancer or 
chemotherapy. All other events were considered unprovoked. The competing event of 
death was identified through active surveillance including calls to participants, search of 
online sources e.g. Social Security Death Index and National Death Index. Further details 
of ascertainment were previously reported.17,18 
 
Statistical Analysis: 
We compared baseline characteristics among participants across eGFRCr-CysC 
and ACR categories using ANOVA for continuous variables and χ2 tests for categorical 
variables. Dichotomous variables were expressed as percentages and continuous variables 
as means ± standard deviation (SD).  
We calculated age, sex and race adjusted incidence rates of VTE per 1000 
person-years with 95% confidence intervals (CI) for each kidney disease measures using 
Poisson regression. We used Cox proportional hazards regression to estimate cause-
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specific hazard ratios (HRs) with 95% CI for the competing risk of VTE and mortality. 
The observation time was defined as time from completing the baseline in-home visit to 
time of lost to follow-up, end of follow-up or event. Participants were censored for death 
in the VTE model, and censored for VTE for the mortality model.19 To control for 
confounding we created a multivariable model including demographics (age, sex, race, 
region of residence) and established VTE risk factors (BMI) to adjust associations of 
kidney disease measures and VTE.  An interaction of race x region for VTE risk was 
previously reported in REGARDS so this interaction term was included in the model.16 
The same covariates were used to estimated adjusted HRs for provoked and unprovoked 
VTE. Mortality models were additionally adjusted for hypertension, diabetes, 
hyperlipidemia, history of cardiovascular disease and smoking. Violations of the Cox 
proportional hazards model assumptions were assessed by visual inspection of the log-
minus-log survival plots and by testing global and individual Schoenfeld residuals. We 
tested for interactions among kidney disease measures and race (black/white), adjusting 
for age, sex and BMI, and stratified by region to account for known interaction between 
race and region. We also tested for an interaction between eGFR and ACR. 
In a secondary analysis, we estimated the HR and 95% CI for VTE using 
eGFRCr, eGFRCysC using the CKD-EPI equation and eGFRCr using the Modification of 
Diet in Renal Disease (MDRD) equation to understand whether a difference in estimating 
equations could account for conflicting reports in the association of kidney disease 
measures and VTE.  
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We calculated the population attributable fraction (PAF) of CKD (using a range 
of eGFRCr-CysC cut points <45, <60 and <90 ml/min/1.73m
2), age ≥65 versus <65 years 
and obesity (BMI>30m/kg2 vs <30 kg/m2) for VTE using the punafcc command in Stata.  
To reconcile our null findings with the literature showing an association of 
albuminuria and VTE we performed a post-hoc sensitivity analysis using estimated 
albumin excretion rate (AER), which is the product of ACR and estimated creatinine 
excretion rate (eCER), using Ix’s formula.20 
eAER= ACR *  (879.89 + 12.51*weight(kg) – 6.19*Age + (34.51 if black) – 
(379.42 if female) ) 
 
Statistical significance was considered as a two-tailed P<0.05, and for interaction 
analyses p<0.10. All statistical analyses were performed by the use of Stata software 
version 14 (StataCorp LP).  
 
2.4. Results 
The initial cohort included 30,239 participants.  After exclusions for missing 
baseline home visit or follow-up data (n=684), self-report of dialysis (n=113) or baseline 
VTE (n=1,741), there were 27,703 participants. A total of 2,601 participants (8.6% of 
initial cohort) were missing any kidney disease measure with the following mutually 
exclusive counts: serum creatinine (n=1,871), serum cystatin C (n=2,518), urine albumin 
(2,002) and urine creatinine (n=1,929). The final analysis included 25,102 participants 
(Figure 2.1.).  
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The analytic cohort was 54% female, 40% black, and 48% age 65 or older. 
There were 9% with eGFRCr-CysC <60ml/min/1.73m
2, 11% with eGFRCr 
<60ml/min/1.73m2, 15% with eGFRCysC <60ml/min/1.73m
2 and 14% with ACR 
>30mg/g. There were 50 participants with ACR>3000mg/g and only one VTE occurred 
in this category. 
Compared to those with higher eGFRCr-CysC at baseline, participants with lower 
eGFRCr-CysC were older, more likely to have hypertension, diabetes, hyperlipidemia, be a 
former or never smoker, and use statins, aspirin or warfarin (Table 2.1.). For higher 
compared to lower ACR categories, diabetes, hypertension, CVD, current smoking were 
more common (Table 2.2.). 
There were 239 VTE events (113 unprovoked, 126 provoked) during 124,624 
person-years follow-up. The incidence rates of VTE with 95% CI are shown in Table 2.3. 
and increased monotonically across categories of declining eGFRCr-CysC. The incidence 
rates of VTE increased across categories of ACR except for the highest category ( 
300mg/g), where the number of events was limited. The incidence rates of mortality 
increased across declining eGFR and higher ACR categories. 
The risk of VTE increased with declining eGFRCr-CysC  (Table 2.4.); the 
unadjusted HRs (95% CI) for eGFRCr-CysC 60-<90, 45-<60 and <45 compared to ≥90 
ml/min/1.73m2 were 1.91 (1.45, 2.51), 2.24 (1.41, 3.57) and 3.38 (2.04, 5.60), p trend 
<0.001. The HRs were attenuated when adjusting for age, sex, race x region and BMI and 
remained statistically significant only for eGFRCr-CysC <45 compared to ≥90 
ml/min/1.73m2, HR 2.13 (1.19, 3.76).  Associations of eGFRCr-CysC, with provoked and 
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unprovoked VTE were similar with a two-fold increased risk for each type of VTE with 
eGFRCr-CysC<45 versus ≥90ml/min/1.73m2(Table 2.4.).   
In the competing risk analysis, the adjusted cause-specific HRs for mortality 
increased with lower eGFRCr-CysC and were higher than the HRs for VTE in each category 
of eGFR (Table 2.4.).  
ACR was not associated with VTE in univariate or multivariable analysis. As 
compared to ACR<10 mg/g, the unadjusted HRs (95% CI) for VTE for ACR 10-<30, 30-
<300 and >300mg/g were 1.30 (0.96, 1.76), 1.54 (1.06, 2.22), and 1.18 (0.52, 2.66). 
Multivariable HRs are shown in Table 2.4.. The HRs were similar for provoked and 
unprovoked VTE (Table 2.4.), and for use of the estimated albumin excretion rate (Table 
2.6., Supplemental Table S2.1.). The adjusted cause-specific HRs for mortality increased 
across higher levels of albuminuria (Table 2.4.). 
Race-specific HRs for VTE by kidney disease measures were stratified by 
region given the known race x region interaction in REGARDS (Table 2.5.). For whites 
residing outside of the southeast, VTE risk increased across categories of eGFRCr-CysC 
with a HR (95% CI) 3.37 (1.34, 8.45) for eGFRCr-CysC <45 ml/min/1.73m
2. For blacks 
residing outside of the southeast, eGFRCr-CysC was not associated with VTE, however the 
interaction p value for race*GFR was 0.70 outside the southeast. In the southeast, 
associations appeared larger in blacks than whites (p interaction = 0.1), with similar 
associations in blacks and whites for eGFR <45 (HR 1.68 and 1.95, respectively) but 
higher HRs among blacks than whites for eGFR 45-<90 ml/min/1.73m2. There were no 
significant differences in the association of ACR with VTE when stratified by race and 
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region (p interaction was 0.9 in southeast, p interaction was 0.3 in non-southeast) (Table 
2.7., Supplemental Table S2.2.). There was also no significant interaction between ACR 
and eGFR (p interaction = 0.4). 
The population attributable fractions of obesity (defined as BMI ≥30 kg/m2) and 
older age (defined as age ≥65 years), for VTE were 17% and 36%, respectively.  The 
population attributable fractions of CKD for VTE by eGFRCr-CysC <90, <60 and eGFRCr-
CysC <45 ml/min/1.73m
2 were 20%, 5% and 4%, respectively.  
In a secondary analysis, the eGFR using alternate equations had similar 
associations with VTE (Table 2.8., Supplemental Table S2.3.). The adjusted HR (95% 
CI) for eGFR <45 compared to ≥90ml/min/1.73m2 was 1.93 (1.13, 3.32) for eGFRCr, and 
1.58 (0.81, 3.08) for eGFRCysC. The HR of VTE with eGFRCr <45ml/min/1.73m
2 using 
the MDRD equation was 1.94 (1.07, 3.50). 
 
2.5. Discussion 
Estimated glomerular filtration rate was independently associated with an 
increased risk of future VTE in this large prospective cohort study. Compared to eGFRCr-
CysC ≥90, an eGFRCr-CysC <45 ml/min/1.73m2 was associated with a 2-fold increased risk 
of VTE, after adjusting for demographic and VTE risk factors. This relationship was 
similar for provoked VTE, but the association was not statistically significant in 
unprovoked VTE. The association of VTE and eGFR appeared to vary by race and 
region, but power limited the interpretation of these analyses. There was no association 
between ACR and incident VTE. The cause-specific hazard ratios for mortality were 
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higher for each eGFR or ACR category than the risk for VTE. The population attributable 
fraction of VTE for CKD was modest compared to that for accepted clinical cut points 
for BMI and older age.  
Our results provide further evidence supporting the relationship between eGFR 
and VTE.7,9,11,21,22 A meta-analysis of five studies, the largest work thus far, demonstrated 
an association between eGFR and VTE risk11 and our findings extend this finding to a 
large, contemporary U.S. cohort. We hypothesized that different eGFR equations used in 
previous research, including individual studies from the meta-analysis, may have led to 
conflicting results on the association of kidney disease measures and VTE. In the ARIC 
and PREVEND studies, eGFRCr by the MDRD equation was not associated with future 
VTE,7,9 however, in ARIC eGFRCysC was associated with VTE. We were able to clarify 
the relationship between kidney disease measures and VTE by simultaneously comparing 
the relationships of the CKD-EPI (eGFRCr, eGFRCysC, eGFRCr-CysC) and MDRD eGFR 
equations, and ACR, with VTE risk in one study. eGFRCr, eGFRCr-CysC and MDRD 
eGFRCr were all significantly associated with VTE risk, in sum, supporting a link 
between kidney disease measures and VTE. With regards to type of VTE, the association 
of eGFR <45 ml/min/1.73m2 was somewhat stronger for provoked VTE than 
unprovoked. Uniformly, the risk of VTE begins at an eGFR below 45 ml/min/1.73m2, 
suggesting the mechanism of the association between eGFR and VTE could relate to 
changes that occur at this level of clearance. 
In contrast to eGFR, ACR was not associated with VTE in this study. This is 
consistent with the finding in ARIC, the only other epidemiologic study of the 
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relationship of ACR and VTE risk performed in the U.S.9 In the Prevention of Renal and 
Vascular End-Stage Disease (PREVEND) study, a Dutch cohort that oversampled for 
albuminuria, urinary albumin excretion was associated with increased risk of future VTE. 
Differences in the cohort composition compared to the REGARDS and ARIC studies 
could account for the different results. In PREVEND there were more smokers (38% vs 
14%), fewer diabetics (4% vs 20%) and lower BMI (mean BMI 26.1 vs 29.2 kg/m2) 
compared to the REGARDS, and people with insulin treated diabetes were excluded. 
Race and regional differences in the risk of VTE have been previously reported 
in the REGARDS study.16 Therefore, we studied whether race modified the association of 
eGFR and VTE within region (southeast/non-southeast). The association of eGFR and 
VTE appeared largest in whites residing outside of the southeast. While this may have 
been a chance finding and power to detect two-way interactions was limited, the reason 
for this finding may be due to the competing risk for death. For eGFR< 45 
ml/min/1.73m2, whites outside the southeast had the lowest cause-specific hazard ratio 
for death, compared to whites in the southeast or blacks in either region. In the 
aforementioned meta-analysis, there was no difference in the association of kidney 
disease and VTE by race. Conflicting results may be related to different definitions of 
kidney disease and limited number of black participants residing outside of the southeast 
included in the meta-analysis.  
There are several strengths of the current study. The large, prospective, 
population based nature of the study enables our results to be generalized to black and 
white Americans living across a geographically diverse region of the U.S. We were able 
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to compare associations of kidney disease measures with VTE using several different 
equations in one study. The study was a contemporary cohort reflecting current trends in 
obesity and medication use (including widespread use of statins) that might alter 
relationships of CKD with VTE, and reflects current diagnosis patterns for VTE, which 
have changed over the past few decades.23 The presentation of competing risk of death is 
unique in the study of kidney disease measures and VTE, and informed our 
understanding of potential race and regional differences in the risk of VTE. 
Limitations of this study require consideration. As with many other prospective 
cohort studies of general populations, GFR was estimated and not measured. The 
estimates of GFR and ACR were obtained once at baseline. This could have led to 
misclassification. The PREVEND study reported that ACR was less accurate and more 
biased than estimated albumin excretion rate,24  because urinary creatinine is influenced 
by muscle mass, introducing confounding based on non-albuminuric covariates.25 
However, in a sensitivity analysis our results were consistent when utilizing estimated 
albumin excretion rate as a predictor. Our analysis may have been limited by low power 
to detect smaller differences in risk of VTE by ACR category. With 239 VTE events and 
a prevalence of 14% ACR>30 mg/g we estimated 80% power to detect a HR of 1.7 or 
higher using alpha<0.05. Despite a large cohort of blacks and whites, power was limited 
in studying both race and region stratified associations of kidney disease measures and 
VTE. The results may not be generalizable to the entire U.S. population as REGARDS 
was limited to self-identified black and white participants above age 45. Finally, while 
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we adjusted for factors known to be associated with VTE risk the results could be 
influenced by unmeasured factors and residual confounding could exist. 
 
2.6. Conclusions 
The present prospective study provides further clarification on a growing 
literature supporting a relationship between kidney function and VTE. In our study, 
eGFR < 45 ml/min/1.73m2 was associated with a two-fold risk of VTE and a three-fold 
risk of mortality. Further study of the mechanisms of the association between low eGFR 
and VTE and potential modifiable risk factors is warranted.  
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Table 2.1.: Baseline characteristics by categories of eGFRCr-CysC 
Characteristic  
(mean, SD or frequency, %) 
eGFRCr-CysC (ml/min/1.73m2) 
 ≥90 60-<90 45-<60 <45 
N 
 
14,087 8,670 1,475 870 
Mean age, years 61.0±8.1 68.5±8.6 72.5±8.8 72.1±9.1 
Sex, female 64.4 40.9 38.2 38.5 
Race, black 35.5 44.6 48.1 54.7 
Region of Residence, southeast 57.3 53.4 52.3 51.7 
 
Hypertension 48.9 67.0 80.1 87.3 
Diabetes 16.1 22.0 34.7 47.5 
Hyperlipidemia 42.1 46.7 51.7 54.4 
CVD 11.1 22.5 37.5 44.0 
     
BMI, kg/m2  28.9±6.1 29.4±6.0 29.7±6.2 30.1±7.0 
Smoking 
   Current 
   Former 
   Never 
 
14.9 
47.9 
37.1 
 
13.6 
42.0 
44.4 
 
12.8 
41.2 
46.0 
 
12.1 
42.2 
45.7 
     
Statin use 27.0 34.5 43.6 47.0 
Aspirin use 37.8 48.7 53.7 57.2 
Hormone Therapy use* 19.2 11.3 11.1 6.9 
Warfarin use 1.4 3.7 7.1 7.7 
     
Serum creatinine (mg/dL) 0.7±0.1 1.0±0.2 1.3±0.2 0.9±0.8 
Serum cystatin C (mg/L) 0.8±0.1 1.1±0.1 1.4±0.2 2.1±0.7 
eGFRcr (ml/min/1.73m2) 96±13 78±13 56±10 37±12 
eGFRcysC (ml/min/1.73m2) 102±14 72±13 49±9 31±9 
Urine ACR (mg/g) 20±108 45±316 123±447 440±987 
*Hormone therapy use for women only. 
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Table 2.2.: Baseline characteristics by categories of albumin-to-creatinine ratio (ACR) 
Characteristic  
(mean, SD or frequency, %) 
ACR (mg/g) 
 <10 10-<30 30-<300 ≥300 
N 15,777 5,696 2,961 668 
     
Mean age, years 63.4±9.0 66.5±9.5 67.3±9.9 66.6±9.3 
Sex, Female 52.9 59.3 50.4 42.4 
Race, Black 37.7 39.5 48.1 63.5 
Region of Residence, Southeast 55.5 56.5 54.3 53.3 
     
Hypertension 51.44 65.5 75.2 87.4 
Diabetes 13.8 25.0 37.4 60.45 
Hyperlipidemia 42.6 46.4 48.7 59.0 
CVD 14.1 20.9 26.3 37.7 
     
BMI, kg/m2  28.9±5.8 29.2±6.4 30.2±6.6 30.7±7.0 
Smoking 
   Current 
   Former 
   Never 
 
13.2 
46.6 
40.2 
 
14.7 
44.8 
40.5 
 
17.6 
41.8 
40.6 
 
20.7 
33.5 
44.7 
     
Statin use 29.0 33.3 36.3 44.5 
Aspirin use 41.3 45.4 46.8 52.9 
HRT use* 19.4 12.2 11.7 8.0 
Warfarin use 2.0 3.4 4.7 4.6 
     
Serum creatinine (mg/dL) 0.9±0.2 0.9±0.3 1.0±0.4 1.5±1.0 
Serum cystatin C (mg/L) 0.9±0.2 1.0±0.3 1.1±0.4 1.6±0.9 
eGFRcr (ml/min/1.73m2) 87±17 85±20 81±24 62±29 
eGFRcysC (ml/min/1.73m2) 90±22 84±24 76±27 55±28 
Urine ACR (mg/g) 5±2 16±5 84±60 1224±1422 
Differences were significant (p <0.05) across categories of ACR for all variables except region of 
residence. *Hormone therapy use for women only. 
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Table 2.3.: Adjusted Incidence Rate (IR) for VTE and mortality per 1000 Person-Years by kidney disease measures 
eGFRCr-CysC 
(ml/min/1.73m2) 
≥90 60-<90 45-<60 <45 p trend 
No. at risk 14,087 8,670 1,475 870  
Person-time 66,171 41,580 6,788 3,720  
No. VTE 90 110 21 18  
VTE IR (95% CI) 1.50 (1.21, 1.85) 2.14 (1.72, 2.66) 2.18 (1.38, 3.46) 3.43(2.09, 5.63) 0.02 
No. deaths 666 1,132 428 378  
Mortality IR (95% CI) 11.4 (10.6, 12.3) 18.5 (17.2, 19.8) 33.5 (30.0, 37.4) 53.4 (47.4, 60.1) <0.001 
ACR (mg/g) <10 10-<30 30-<300 ≥300  
No. at risk 15,777 5,696 2,961 668*  
Person-time 75,273 26,732 13,347 2907  
No. VTE 135 62 36 6  
VTE IR (95% CI) 1.69 (1.42, 2.02) 1.97(1.52, 2.56) 2.16 (1.54, 3.04) 1.70(0.76, 3.81) 0.5 
No. deaths 1,020 738 601 245  
Mortality IR (95% CI) 11.4 (10.7, 12.2) 19.1 (17.6, 20.6) 28.0 (25.6, 30.7) 54.6 (47.8, 62.2) <0.001 
eGFR is expressed in ml/min/1.73m2 and ACR in mg/g. *Of the 50 participants with ACR>3000mg/g only one VTE in this 
category. Incidence rates are adjusted for age, sex and race.  
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Table 2.4.: Cause specific hazard ratios (95% CI) for total VTE, provoked and unprovoked VTE and mortality by kidney disease measures 
eGFRCr-CysC ≥90 60-<90 45-<60 <45 p trend 
Crude VTE HR 1.0 (ref) 1.91 (1.45, 2.51) 2.24 (1.41, 3.57) 3.38 (2.04, 5.60) <0.001 
Adjusted VTE HR 
Total 
 
1.0 (ref) 
 
1.28 (0.94, 1.76) 
 
1.30 (0.77, 2.18) 
 
2.13 (1.21, 3.76) 
0.01 
Provoked 1.0 (ref) 1.13 (0.73, 1.75) 1.39 (0.69, 2.79) 2.31 (1.07, 4.96) 0.03 
Unprovoked 1.0 (ref) 1.47 (0.93, 2.32) 1.20 (0.55, 2.64) 1.98 (0.86, 4.61) 0.2 
Crude mortality HR 1.0 (ref) 2.53 (2.29, 2.78) 6.09 (5.39, 6.89) 10.04 (8.84, 11.41) <0.001 
Adjusted mortality HR 1.0 (ref) 1.40 (1.26, 1.57) 2.28 (1.97, 2.64) 3.18 (2.72, 3.71) <0.001 
ACR <10 10-<30 30-<300 ≥300 p trend 
Crude VTE HR 1.0 (ref) 1.30 (0.96, 1.76) 1.54 (1.06, 2.22) 1.18 (0.52, 2.66) 0.6 
Adjusted VTE HR 
Total 
 
1.0 (ref) 
 
1.14 (0.84, 1.55) 
 
1.15 (0.79, 1.68) 
 
0.65 (0.26, 1.64) 
0.4 
Provoked 1.0 (ref) 1.38 (0.91, 2.09) 1.42 (0.85, 2.36) 0.53 (0.13, 2.25) 0.4 
Unprovoked 1.0 (ref) 1.92 (0.58, 1.45) 0.92 (0.52, 1.64) 0.78 (0.24, 2.59) 0.7 
Crude mortality HR 1.0 (ref) 2.07 (1.88, 2.28) 3.41 (3.08, 3.78) 6.42 (5.58, 7.40) <0.001 
Adjusted mortality HR 1.0 (ref) 1.46 (1.32, 1.62) 1.94 (1.74, 2.20) 2.60 (2.20, 3.06) <0.001 
eGFR is expressed in ml/min/1.73m2 and ACR in mg/g. VTE Cox models are adjusted for age, sex, race x region, BMI. Cox models for mortality are 
additionally adjusted for hypertension, diabetes, hyperlipidemia, cardiovascular disease and smoking. Adjusted ACR models are adjusted for eGFR and 
vice versa. 
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Table 2.5.: Adjusted Cause-Specific Hazard Ratios and 95% Confidence Intervals for VTE and mortality by eGFRCr-CysC stratified by race and 
region 
  eGFR 90 60-<90 45-<60 <45 p trend 
VTE Southeast White 1.0 1.21 (0.72, 2.03) 0.30 (0.07, 1.31) 1.95 (0.76, 4.99) 0.7 
  Black 1.0 2.18 (1.06, 4.46) 3.45 (1.28, 9.31) 1.68 (0.36, 7.82) 0.4 
p interaction race x eGFR= 0.1 
 Non-southeast White 1.0 1.09 (0.61, 1.97) 1.64 (0.64, 4.11) 3.37 (1.34, 8.45) 0.007 
  Black 1.0 0.89 (0.39, 2.02) 1.05 (0.33, 3.33) 1.04 (0.26, 4.10) 0.9 
p interaction race x eGFR= 0.7 
Mortality Southeast White 1.0 1.44 (1.20, 1.72) 2.25 (1.76, 2.88) 3.03 (2.31, 3.98) <0.001 
  Black 1.0 1.24 (0.95, 1.60) 1.99 (1.41, 2.81) 3.15 (2.20, 4.50) <0.001 
p interaction race x eGFR <0.001 
 Non-southeast White 1.0 1.33 (1.06, 1.66) 2.12 (1.59, 2.84) 2.29 (1.64, 3.19) <0.001 
  Black 1.0 1.46 (1.14, 1.88) 2.37 (1.73, 3.25) 3.36 (2.40, 4.69) <0.001 
p interaction race x eGFR <0.001 
eGFRCr-CysC in ml/min/1.73m2. VTE Hazard ratios are adjusted for age, sex and BMI. Mortality HR are additionally adjusted for hypertension, diabetes, 
hyperlipidemia, cardiovascular disease, smoking and albuminuria. 
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Table 2.6.: (Supplemental Table S2.1.): Age, sex and race adjusted Incidence rate per 1000 Person-Years and Hazard Ratio (95% CI) of VTE for 
categories of estimated albumin excretion rate (eAER) 
eAER <15 15-<30 30-<300 ≥300 P trend 
No. at risk 848 2,548 12,875 8,831  
Person-time 3,816 11,897 61,579 40,967  
No. VTE 6 16 128 89  
Incidence rate (95% CI) 1.54  
(0.69, 3.44) 
1.25  
(0.76, 2.04) 
1.88  
(1.57, 2.26) 
1.90  
(1.52, 2.39) 
 
Crude HR 1.0 0.84  
(0.33, 2.13) 
1.27  
(0.56, 2.89) 
1.35  
(0.59, 3.09) 
0.3 
Adjusted HR 1.0 0.84 
(0.33, 2.18) 
1.35 
(0.59, 3.09) 
1.22 
(0.51, 2.91) 
0.4 
eAER is estimated albumin excretion rate in mg/24hr. eGFR in ml/min/1.73m2. Adjusted model is adjusted for age, sex, race, region and race*region and 
BMI and eGFRCr-CysC. 
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Table 2.7 (Supplemental Table S2.2.): Adjusted Cause-Specific HRs (95% CI) for VTE and mortality by ACR stratified by race and region 
  ACR <10 10-<30 30-<300  300 P trend 
VTE Southeast White 1.0 1.04 
(0.62, 1.75) 
1.09 
(0.56, 2.12) 
0.54 
(0.74, 3.93) 
0.6 
  Black 1.0 1.19 
(0.60, 2.39) 
1.35 
(0.60, 3.01) 
1.27 
(0.30, 5.39) 
0.7 
P interaction race x ACR= 0.9 
 Non-southeast White 1.0 1.60 
(0.94, 2.71) 
1.15 
(0.53, 2.49) 
0.99 
(0.14, 7.24) 
0.9 
  Black 1.0 0.64 
(0.26, 1.61) 
1.43 
(0.65, 3.15) 
0.55 
(0.07, 4.11) 
0.9 
P interaction race x ACR= 0.3 
Mortality Southeast White 1.0 1.51  
(1.28, 1.79) 
2.02  
(1.67, 2.44) 
2.30  
(1.67, 3.16) 
<0.001 
  Black 1.0 1.32  
(1.03, 1.69) 
1.82  
(1.40, 2.37) 
2.53  
(1.76, 3.64) 
<0.001 
P interaction race x ACR <0.001 
 Non-southeast White 1.0 1.37  
(1.11, 1.67) 
1.84  
(1.46, 2.33) 
2.47  
(1.66, 3.66) 
<0.001 
  Black 1.0 1.47  
(1.16, 1.85) 
1.99  
(1.57, 2.54) 
2.98  
(2.20, 4.02) 
<0.001 
P interaction race x ACR <0.001 
ACR in mg/g. VTE Hazard ratios are adjusted for age, sex, BMI and eGFRCr-CysC. Mortality HR are additionally adjusted for hypertension, diabetes, history 
of cardiovascular disease, smoking. 
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Table 2.8.: (Supplemental Table S2.3.): Incidence Rates Per 1000 PY and Hazard Ratio (95% CI) of VTE for eGFR equations 
CKD-EPI eGFRCr  ≥90 60-<90 45-<60 <45 P trend 
No. events/N at risk 93/11,433 114/11,013 22/1,799 20/857  
Person-time 53,464 52,855 8,244 3,696  
Incidence Rate  
(95% CI) 
1.91 (1.56, 2.36) 1.69 (1.37, 2.08) 1.77 (1.13, 2.76) 3.43 (2.15, 5.48) 0.02 
Crude HR for VTE 1.0 (ref) 1.23 (0.93, 1.63) 1.62 (1.02, 2.59) 3.35 (2.06, 5.45) <0.001 
Adjusted HR for 
Total VTE 
1.0 (ref) 0.86 (0.63, 1.17) 0.92 (0.56, 1.53) 1.93 (1.13, 3.32) 0.02 
Provoked VTE 1.0 (ref) 0.76 (0.50, 1.17) 0.76 (0.36, 1.57) 1.96 (0.95, 4.06) 0.09 
Unprovoked VTE 1.0 (ref) 1.00 (0.63, 1.57) 1.15 (0.57, 2.32) 1.94 (0.87, 4.31) 0.1 
CKD-EPI eGFRCysC      
No. events/N at risk 84/11,971 103/9,401 35/2,316 27/1,414  
Person-time 56,159 45,322 10,740 6,039  
Incidence Rate  
(95% CI) 
1.61 (1.30, 2.00) 1.90 (1.54, 2.34) 2.32 (1.61, 3.33) 2.98 (1.97, 4.49) 0.01 
Crude HR for VTE 1.0 (ref) 1.45 (1.09, 1.95) 2.07 (1.38, 3.10) 3.01 (1.93, 4.68) <0.001 
Adjusted HR for 
Total VTE 
1.0 (ref) 1.02 (0.74, 1.39) 1.10 (0.70, 1.74) 1.58 (0.95, 2.62) 0.08 
Provoked VTE 1.0 (ref) 0.78 (0.50, 1.20) 0.93 (0.50, 1.74) 1.58 (0.81, 3.08) 0.2 
Unprovoked VTE 1.0 (ref) 1.36 (0.85, 2.18) 1.36 (0.70, 2.63) 1.62 (0.75, 3.47) 0.2 
MDRD eGFRCr      
No. events/N at risk 78/9,494 118/12,896 24/1,883 14/636  
Person-time 44,045 62,040 8,587 2,809  
Incidence Rate (95% CI) 1.79 (1.42, 2.24) 1.69 (1.39, 2.05) 2.06 (1.35, 3.14) 3.54 (2.06, 6.09) 0.42 
Crude HR for VTE 1.0 (ref) 1.05 (0.79, 1.40) 1.58 (1.00, 2.50) 2.84 (1.61, 5.02) <0.001 
Adjusted HR for 
Total VTE 
1.0 (ref) 0.95 (0.70, 1.27) 1.07 (0.66, 1.73) 1.94 (1.07, 3.50) 0.03 
Provoked VTE 1.0 (ref) 0.88 (0.59, 1.32) 0.94 (0.47, 1.88) 1.81 (0.79, 4.16) 0.2 
Unprovoked VTE 1.0 (ref) 1.03 (0.66, 1.59) 1.22 (0.62, 2.45) 2.12 (0.92, 4.92) 0.06 
eGFR in ml/min/1.73m2. Incidence rates are adjusted for age, sex and race. Adjusted Cox models are adjusted for age, sex, race, region and race*region, 
BMI and ACR
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Figure 2.1.: Flow diagram of participants included in the study. Mutually exclusive 
counts in parentheses. 
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3.1. Abstract 
Background: Chronic kidney disease (CKD) is associated with venous 
thromboembolism (VTE) risk via unknown mechanisms. Whether strategies protective 
against VTE in the general population might work in CKD is unknown.  
Objectives: To determine whether biomarkers of thrombosis risk attenuate VTE risk and 
if factors protective against VTE were similarly effective in people with CKD. 
Methods: With 4.3 years of follow up, baseline biomarkers were measured in 294 
incident VTE cases and 939 non-cases from the REGARDS cohort, a nationwide cohort 
of 30,239 persons age 45 and older. The hazard ratio (HR) of VTE per 10 ml/min/1.73m2 
lower eGFR, and the percent attenuation of this HR by each biomarker were calculated. 
Associations of protective factors, physical activity, lower BMI, aspirin, warfarin and 
statin use, with VTE were estimated in those with and without CKD. 
Results: The adjusted HR (95% CI) for VTE with lower eGFR was 1.13 (1.02, 1.25), and 
this was attenuated 23% (5, 100%) by D-dimer, 100% (50, 100%) by FVIII and 15% (2, 
84%) by CRP. Normal BMI was associated with lower VTE risk in those without CKD 
(HR 0.47 (0.32, 0.70)) but not with CKD (HR 1.07 (0.51, 2.22) p interaction 0.07). Statin 
use, physical activity and warfarin use were associated with lower VTE risk in both 
groups. 
Conclusions: Procoagulant and inflammatory biomarkers mediated the association of 
eGFR with VTE.  Higher physical activity, statin and warfarin use mitigated risk of VTE 
in those with and without CKD, but normal BMI did not mitigate risk in CKD.  
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3.2. Introduction 
Kidney disease has recently emerged as a risk factor for venous 
thromboembolism (VTE),[1-4] however little is known about mechanisms or clinical 
implications of this relationship. Low estimated glomerular filtration rate (eGFR) is 
associated with increased levels of biomarkers of inflammation and procoagulation, 
including higher levels of C-reactive protein (CRP), D-dimer and factor VIII (FVIII).[5-
7]. Since these alterations are also associated with increased VTE risk,[8-19] they might 
account for the relationship of kidney disease with VTE. That is, CKD induced 
inflammation and procoagulation may explain part of the relationship between eGFR and 
VTE and thus could be considered as mediators. If this is the case, then interventions that 
have an impact on the biology represented by these biomarkers could lower VTE risk 
associated with CKD. 
Epidemiology studies and clinical trials suggest a normal BMI, higher physical 
activity,[20-22] statins,[23-25] aspirin and anticoagulants[26-28] reduce the risk of VTE. 
However, it is not known if these factors that are protective in the general population are 
similarly protective in patients with CKD. Knowledge of whether a particular factor is 
equally, or more, effective in CKD could also shed light on potential mechanisms of VTE 
in CKD.  
In this analysis, we evaluated whether higher levels of D-dimer, Factor VIII 
(FVIII) and C-reactive protein (CRP), would attenuate the association of eGFR and VTE. 
We also evaluated whether established risk factors and protective medication use exert 
similar associations with VTE risk in individuals with versus without CKD.  
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3.3. Methods 
Study population and design:  
We studied participants in the Reasons for Geographic and Racial Differences in 
Stroke (REGARDS) cohort, a prospective cohort study of self-reported blacks and whites 
in the United States, which has been previously described.[29] In brief, REGARDS 
enrolled 30,239 black and white women and men age 45 and older between 2003-2007. 
Exclusion criteria included medical conditions preventing long-term participation, active 
cancer or active treatment for cancer, residence in or awaiting placement in a nursing 
home, or inability to communicate in English. For this analysis, we excluded participants 
missing baseline measures of kidney function (serum creatinine and cystatin C), those 
with prior self-reported VTE or receiving dialysis at baseline. 
Participants were identified from a commercially available list of U.S. residents 
and recruited through a mailing followed by telephone contact. The cooperation rate was 
49% of eligible participants. After completing a computer assisted telephone interview, 
participants underwent an in-home visit, where informed consent was obtained, 
anthropomorphic data, medication inventory and urine samples were collected and 
fasting phlebotomy and an electrocardiogram were performed. Two blood pressure 
measurements were averaged for analysis, and blood samples were collected after a 10 to 
12 hour fast. Blood was centrifuged locally and shipped on ice packs to the University of 
Vermont for reprocessing and analysis or storage.[30] The study was approved by all 
institutional review boards at participating universities.  
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Event ascertainment and definitions:  
The primary outcome was incident VTE, consisting of deep vein thrombosis 
(DVT), pulmonary embolism (PE) or both occurring together. Events were ascertained 
and validated as previously described.[31] In brief, VTE events were identified by four 
methods: review of reasons for hospitalization from telephone calls every 6 months up to 
February 2010; a telephone interview administered from February 2010-February 2011 to 
identify any self-report of VTE from baseline to time of the call; review of all deaths 
using periodic searches of the National Death Index, exit interviews or records of last 
hospital stay; review of medical records for other events such as stroke. For potential 
cases, in-patient and outpatient medical records were retrieved and then reviewed and 
adjudicated by two physicians. Major disagreements were settled by a blinded third 
physician.  
Estimated glomerular filtration rate (eGFR) was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation[32] based on 
creatinine and cystatin C.[33] Baseline covariates of interest included age, sex, race (self-
reported black or white), region of residence (southeast or non-southeast), body mass 
index (BMI) in kg/m2, diabetes, hyperlipidemia, cardiovascular disease (CVD), physical 
activity frequency (self-report of 0, 1-3 or 4 or more times per week), self-report of 
regular aspirin use, and statin or warfarin use determined by pill bottle review. Southeast 
was defined as residing in Alabama, Arkansas, Georgia, Louisiana, Mississippi, North 
Carolina, South Carolina or Tennessee. Diabetes was defined as fasting glucose 126 
mg/dL, random glucose 200 mg/dL, or taking insulin or glucose lowering medications. 
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Hyperlipidemia was defined as cholesterol >240 mg/dL, low density lipoprotein >160 
mg/dL or taking medications for high cholesterol. CVD was defined as self-report of pre-
baseline myocardial infarction, coronary artery surgery, angioplasty, stenting, silent MI 
on electrocardiogram or stroke. CKD was defined as eGFR less than 60 ml/min/1.73m2 
by convention In REGARDS, albuminuria was not associated with VTE[1] so this was 
not considered. Normal BMI was defined as 18.5- <25 kg/m2.  
 
Case-Cohort Study Design: 
We used previously measured biomarker data for D-dimer and FVIII from a 
cohort random sample (CRS), selected as previously described.[34] The CRS was 
randomly selected within strata of race, sex and age to ensure sufficient representation of 
high-risk groups. To these data, we added measurement of these biomarkers in 294 VTE 
cases. For analyses conducted in this case-cohort sample we excluded participants 
missing lab data (Table 3.6., Supplemental Table S3.2.). 
 
Laboratory:  
In the full cohort, serum creatinine was measured using an isotope-dilution mass 
spectrometry-traceable method using the Vitros 950IRC instrument (Johnson & Johnson 
Clinical Diagnostics, Rochester, NY), with a coefficient of variation (CV) of 1.1%. 
Serum cystatin C was measured with high sensitivity particle-enhanced 
immunonephelometry (N Latex Cystatin C on the BNII, Dade Behring, Deerfield, IL), 
with an intra-assay CV of 2.0-2.8% and an inter-assay CV of 2.3-3.1%. CRP was 
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measured by particle enhanced immunonephelometry using the BNII nephelometer (N 
High Sensitivity CRP, Dade Behring, Deerfield, IL) with inter-assay CV of 2.1–
5.7%.[35]   
For this VTE case-cohort study, D-dimer and FVIII were measured in 2015 in 
VTE cases and harmonized with measurements made previously in the CRS in 2012. The 
CRS D-dimer was run in plasma using an immunoturbidometric assay on the STA-R 
analyzer (Diagnostica Stago, Asnières sur Seine, France; inter-assay CV 3.2-27.1%) and 
VTE cases were run on the STA-R Evolution analyzer (Diagnostica Stago, Asnières sur 
Seine, France; inter-assay CV 1.5-21.7%). FVIII was measured using an ELISA with a 
CV of 4-7% (Enzyme Research Laboratories, South Bend, IN), with units of % of 
normal. 
Given that analytes in cases and the cohort sample were measured at two 
different times, and for D-dimer with two different analyzers, we evaluated for analytical 
drift in assay results using three approaches (Table 3.7., Supplemental Table S3.2.). We 
detected a laboratory shift in D-dimer values after the introduction of a new analyzer in 
2014, which was verified in a set of experiments. There was no analytic drift observed for 
FVIII, however, the correlation between analytes in 2012 and 2015 was weaker, which 
we attributed to higher analytical CVs. To harmonize results, we adjusted the D-dimer 
values for VTE cases down by 0.05 µg/mL. 
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Statistical analysis:  
In this report, we examine both the potential of mediation for selected biomarker 
and effect modification by CKD status.   
For the mediation analysis, we compared baseline characteristics among 
participants with VTE and those in the cohort sample using chi-squared tests and t-tests 
as appropriate. D-dimer and CRP were highly skewed and thus natural log transformation 
was used for the analyses. We present back-transformed (geometric) means (95% CI) of 
log transformed variables in the results. We used linear regression to study the cross-
sectional association of eGFR and biomarker levels (D-dimer, FVIII and CRP). We 
adjusted for demographics (age, sex, race and region of residence), and covariates that are 
known to be related to these biomarkers: BMI, hypertension, hyperlipidemia, diabetes, 
history of cardiovascular disease and smoking. Cox proportional hazards models were 
used to determine the hazard ratio (HR) for VTE per SD increment of each biomarker. 
Those without an event or who died of non-VTE related causes were censored at that 
time or at the time of last follow-up, whichever occurred first. We accounted for 
population weighting of the CRS using the Barlow method.[36] A base model adjusted 
for age, sex, race, region and BMI.  We calculated the adjusted HR of VTE per 10-unit 
lower eGFR, then added each biomarker separately to the base model. To estimate the 
magnitude of the potential mediation of the association of CKD with VTE by each 
biomarker we calculated the percent attenuation of the HR: Percent attenuation = 100% x 
(HR without biomarker – HR with biomarker) /(HR without biomarker – 1). The 95% CI 
of the percent attenuation of the HR for eGFR and VTE was calculated using 
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bootstrapping with replacement with 1000 replicate samples. If the percent mediation was 
greater than 100% we reset that value to 100%. To verify that our results from the case-
cohort study were representative of the full REGARDS study, we performed a sensitivity 
analysis by repeating the same analysis with CRP, which was measured in the entire 
cohort, and presented these results for qualitative comparison.  
To study effect modification by CKD status, in the full cohort we obtained risk-
estimates for established VTE risk factors and protect medication use from stratified Cox 
models with CKD as the stratification variable. We formally tested for an interaction 
between each protective factor and CKD using interaction terms, interpreted as 
significant if p interaction <0.10. Models were adjusted for age, sex, race, region and 
BMI.   
Violations of the proportional hazards assumption were tested visually and with 
Schoenfeld tests. For the primary predictor (eGFR), non-proportionality was further 
tested with an interaction term, eGFR x time, and HR were estimated at various time 
points. For FVIII, Schoenfeld testing demonstrated significant violation of the 
proportional hazards assumption but this was not confirmed with observed vs predicted 
plots or smoothed estimates of the log HR.  All statistical analyses were performed using 
Stata software version 14 (StataCorp LP, College Station, TX) and SAS version 9.4 (SAS 
Institute Inc., Cary, NC).  
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3.4. Results 
 The case-cohort sample included 1,467 participants, with 386 being VTE 
cases. Among these, after excluding those with missing measures of kidney function (n= 
88), study biomarkers (n=9), receiving dialysis (n=9), or who reported pre-baseline VTE 
(n= 143), there were 1,233 participants in the case-cohort sample (294 VTE cases) (Table 
3.6., Supplemental Table S3.1.).  
The VTE cases were more likely to be male and white compared to non-cases. 
Comorbid conditions were similar between cases and non-cases other than BMI which 
was higher in cases. The eGFR was lower in VTE cases than the cohort sample, and 
markers of inflammation and procoagulation were higher (Table 3.1.). 
Lower eGFR was associated with higher levels of biomarkers of inflammation 
and procoagulation. In the cohort sample, adjusting for demographics and cardiovascular 
risk factors, each 10 ml/min/1.73m2 lower eGFR was associated with a higher level of 
natural log (ln) D-dimer 0.05 µg/mL (95% CI 0.01 0.08), Factor VIII 6.6% (95% CI 4.5, 
8.4%) and ln-CRP 0.08 mg/L (95% CI 0.04, 0.15) (Table 3.2.). The adjusted HRs of VTE 
were 1.69 (95% CI 1.49, 2.02) per SD higher ln-D-dimer, 2.23 (95% CI 1.98, 2.62) per 
SD higher FVIII and 1.29 (1.09, 1.52) per SD higher ln-CRP (Table 3.3.). 
 Mean follow-up time was 4.3 years. The eGFR was inversely associated 
with VTE risk. For each 10 ml/min/1.73m2 lower eGFR, the HR (95% CI) for VTE was 
1.13 (1.02-1.25), after adjusting for demographics and VTE risk factors. After adjusting 
for ln-D-dimer, Factor VIII and ln-CRP individually, the HRs (95% CI) for VTE were 
attenuated 1.10 (0.99, 1.21), 0.98 (0.87, 1.11) and 1.11 (1.00, 1.22) respectively (Table 
 85 
 
3.4.). Including all three biomarkers the HR was 0.99 (0.88-1.11). The percent 
attenuation of the HRs (95% CI) were 23% (5,100%) for ln-D-dimer, >100% (50, 100%) 
for Factor VIII, 15% (2, 84%) for ln-CRP and >100 % (44, 100%) for all three 
biomarkers (Figure 3.1.).  
 The proportional hazards assumption may have been violated for eGFR and 
FVIII. Stratification of FVIII at median FVIII values demonstrated proportional hazards 
for VTE. There was a statistically significant interaction between eGFR and time, thus 
we modeled the HR for VTE at 1, 3 and 5 years follow up. The association of eGFR and 
VTE decreased over time but attenuation by FVIII was similar across follow up time 
periods. (Table 3.8., Supplemental Table S3.3.).  
 In a sensitivity analysis utilizing the full cohort, for each 10 ml/min/1.73m2 
decrease in eGFR the age, sex, race and BMI-adjusted HR (95% CI) of VTE was 1.09 
(1.02, 1.16). After the addition of ln-CRP the HR (95% CI) was 1.07 (1.00, 1.15), for a 
percent attenuation (95% CI) of 22% (5-69%). 
 The association of mitigating factors for risk of VTE were assessed in the 
full cohort, and stratified by CKD status, with results shown in Table 3.5.. Statin use was 
associated with a reduced risk of VTE; the HR was 0.68 (95% CI 0.50, 0.93) in the full 
cohort with a similar HR in the non-CKD group, and a weaker relationship in the CKD 
group, although this difference was not statistically significant (p interaction of statin use 
and CKD 0.61). In the full cohort and in those without CKD, normal BMI was associated 
with a ~50% lower risk of VTE, but there was no association in those with CKD (p 
interaction BMI and CKD = 0.07). We observed inverse associations of warfarin use and 
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physical activity with VTE which were similar in those with and without CKD, although 
the 95% confidence intervals for these HRs included 1.0. Aspirin use was not associated 
with risk of VTE in the full cohort, or in those with or without CKD. 
 
3.5. Discussion 
 In this prospective study, the association of eGFR with VTE was attenuated 
by D-dimer, CRP and in particular Factor VIII.  Overall, normal BMI was strongly 
protective against VTE, but this relationship was present only for those without CKD, 
and was absent in those with CKD. Statin use was associated with reduced risk of VTE 
overall, and this association was weaker in those with compared to without CKD, 
although this difference was not statistically significant. Warfarin use and physical 
activity were similarly associated with reduced risk of VTE in both those with and 
without CKD. Baseline aspirin was not associated with lower risk of VTE in either those 
with or without CKD. 
 Our findings suggest that CKD-induced activation of inflammation and 
procoagulation are in the causal pathway between eGFR and VTE. We confirmed prior 
literature that the studied biomarkers D-dimer[5, 7, 37] FVIII[4, 5, 7] and CRP[38, 39] 
are more adverse with worsening kidney function (confirming our rationale to choose 
them for this study). We also confirmed that D-dimer,[8] FVIII[10, 18] and CRP[14] 
were strongly associated with VTE. We are aware of only one prior study of mediators of 
the relationship between eGFR and VTE; The Multiple Environmental and Genetic 
Association (MEGA) case-control study included 2,473 patients with recent VTE and 
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2,936 matched controls in the Netherlands between 1999-2004 and accounted for genetic 
mutations and confounders such as recent surgery or immobilization.[4] Similar to 
findings here, adjustment for FVIII or von Willebrand factor (vWF) measured after the 
VTE fully explained the association of eGFR and VTE,  supporting the conclusion of 
both studies that FVIII and/or vWF may mediate the association of kidney function with 
VTE. In that study, there was no mediation by anticoagulant factors, including protein C, 
protein S or antithrombin. One limitation of the MEGA study is that blood samples were 
collected three months after the VTE, thus biomarkers might have been elevated due to 
the recent thrombosis, and eGFR might have changed after the VTE as well. VTE may 
also have caused greater increases in FVIII and vWF in those with versus without CKD, 
possibly explaining the observed mediation. In our study, kidney function and biomarkers 
were measured at baseline, prior to the VTE, and participants with previous VTE were 
excluded from the analyses. Our findings confirmed the MEGA findings, reducing the 
likelihood that the discussed factors were important limitations in that study, and 
strengthening a conclusion that FVIII and/or vWF are mediators of this association. 
Unlike MEGA, we evaluated inflammation, as measured by CRP, and coagulation 
activation, measured by D-dimer, as potential mediators of the association of eGFR and 
VTE.  The risk of VTE was attenuated by both biomarkers, but to a lesser extent than by 
FVIII. An alternative explanation for both studies findings is that these biomarkers are 
confounders but not mediators of the association of CKD with VTE. We are not aware of 
other studies addressing these two biomarkers. 
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 Given our finding that FVIII played a larger role in the association of eGFR 
and VTE than CRP or D-dimer, further discussion is warranted, specifically on the 
potential role of FVIII as mediator in the association of eGFR with VTE.  FVIII is a 
glycoprotein procofactor that is essential to coagulation. It is produced in liver sinusoidal 
cells and endothelial cells and circulates bound to vWF in an inactivated form. When 
blood vessel injury occurs, it separates from vWF and acts a cofactor in the conversion of 
Factor IX to Factor IXa. When not bound to vWF, FVIII is rapidly catabolized in 
circulation via LDL-receptor-related protein (LRP), a hepatic clearance receptor that is 
reduced in kidney disease.[40-42] Our model that included all three biomarkers had 
similar point estimates to that of the model with just FVIII. One possibility for this is that 
inflammation as measured by CRP and procoagulation as measured by D-dimer exert 
their effects upstream, by promoting FVIII activity or by impairing FVIII degradation. 
Despite the potential joint mechanisms by which inflammation and procoagulation may 
be increasing the risk of VTE in CKD, Factor VIII appears to play a larger role. FVIII has 
an established role in the etiology other cardiovascular diseases[43, 44]  and in 
progression of CKD as well[45-47]. 
 As CKD has only recently emerged as a risk factor for VTE, there is little 
data on primary prevention of VTE in CKD. Here, we studied the potential for lifestyle 
factors and medications to reduce the risk of VTE in those with and without CKD by 
determining if there was an interaction between CKD and a protective factor. If we found 
a factor was associated with reduced risk of VTE in CKD it might elucidate mechanisms 
of VTE in CKD and point to interventions that could be useful to lower the risk. Our 
 89 
 
findings raise hypotheses that warfarin use, statin use and higher physical activity might 
mitigate VTE risk in those with CKD, although power limited our interpretations in some 
cases leading to confidence intervals that included 1.0.   Considering warfarin use, we 
excluded those who had prior VTE, so participants presumably had a different indication 
for warfarin, e.g. atrial fibrillation or a mechanical heart valve.  The wide confidence 
intervals (particularly in the CKD group) may be due to low numbers of events, 
imprecision of the predictor (i.e. baseline use not reflecting use at time of the VTE), 
under-dosing in CKD (due to concern for bleeding, alterations in non-renal clearance), or 
difficulties in achieving stable international normalized ratios in CKD. Whether warfarin 
would be practical in primary prevention of VTE in those with CKD would require a 
randomized controlled trial to determine, and must take into account the bleeding risk, 
which might offset any protective effect.[48, 49] Our finding related to statin use 
confirms prior work[24, 50]  and suggests further study of statins (which do not cause 
bleeding) in VTE prevention in CKD patients. Our finding of no association of regular 
aspirin use with VTE risk agree with prior research.[51] An association of increased 
physical activity with lower VTE risk has been reported previously[20, 21] further study 
of its role in VTE prevention seems worthy. In contrast, our findings suggest that 
attaining a normal BMI might lower VTE risk in those without CKD, but not in those 
with CKD. One hypothesis to explain this is that the inflammatory or pro-coagulant 
pathways of CKD outweigh any impact that normal BMI might have in reducing VTE 
risk in CKD. Alternatively, lower BMI in CKD may be due to unmeasured confounding 
illness, which would mask a protective effect of lower BMI for VTE. 
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 There are several strengths to this study. This was a prospective study where 
kidney function and biomarker levels were measured prior to onset of VTE, and this 
might better elucidate mechanistic pathways of CKD-related VTE risk. The study was a 
contemporary cohort that reflects current use of statins and trends in obesity and diabetes 
relevant to the U.S. population. We had excellent representation of white and black 
participants, unlike many studies of VTE epidemiology. In addition, we evaluated the 
role of lifestyle factors in risk of VTE stratified by CKD status, to attempt to develop 
hypotheses for how CKD patients could reduce their risk of VTE. 
 There are limitations of this study to consider. The biomarkers were 
measured at baseline which may have led to misclassification if biomarker level changed 
prior to the VTE. The biomarkers in cases were measured later than the cohort random 
sample, and in some cases with different analyzers, but we took several steps to 
harmonize the data. Also, we were unable to determine whether low eGFR preceded or 
was the result of inflammation and procoagulation. It is possible that inflammation and 
procoagulation cause both CKD and VTE through independent pathways. That is, 
misclassification of the mediator, unknown confounding between mediator and outcome 
and interaction between mediator and exposure are potential limitations. We 
demonstrated that the association of eGFR and VTE decreased with time, which may 
have led to underestimation of the effect size and the mediation by biomarkers. Due the 
blood sample processing methods in REGARDS we were unable to evaluate the role of 
platelet function, proteins released by platelets or vWF,[30] all of which may be other 
factors linking CKD with VTE. Warfarin is known to reduce the risk of VTE but the 
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association was weaker than might be expected in our study. Reasons for this could be 
insufficient power to detect this association given only 3% of the cohort reported 
warfarin use or failure of baseline use to reliably indicate continuous use up to the time of 
VTE.  Direct oral anticoagulants could not be evaluated here due to the time when the 
study was performed. Finally, although we adjusted for established VTE risk factors, 
there may be other factors not considered that would lead to residual confounding.  
 
3.6. Conclusion 
 In this study, markers of inflammation and procoagulation that are associated 
with both lower eGFR and VTE may mediate the association of eGFR and VTE. Normal 
BMI was protective against VTE but not in participants with CKD. Higher physical 
activity, statin and warfarin use mitigated risk of VTE in those with and without CKD, 
offering possible targets for intervention studies.   Additional studies are necessary to 
confirm whether biomarkers like FVIII might serve as surrogate markers in trials to 
reduce the risk of VTE in CKD. 
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Table 3.1.: Baseline characteristics of REGARDS case-cohort participants 
Characteristic No VTE  
N=939 
VTE 
N=294 
Age (years) 68 ± 12 69 ± 8 
Female 49 41 
Black 49 38 
Southeast 52 53 
   
Hypertension 60 64 
Diabetes 20 20 
Hyperlipidemia 41 41 
Cardiovascular disease 19 23 
.0 28.7 ± 5.8 30.2 ± 5.7 
   
Physical activity   
- 0 x week 35 41 
- 1-3 x week 36 35 
- 4+ x week 29 25 
   
Smoking   
- Current 15% 12% 
- Never 48% 42% 
- Past 37% 46% 
   
eGFR ml/min/1.73m2 87 ± 23 80 ± 21 
   
D-dimer (median, IQR) µg/ml 0.5 (0.3-0.9) 0.7 (0.4 - 1.2) 
FVIII % 124 ± 45 165 ± 60 
CRP (median, IQR) mg/L 2.1 (0.9- 4.9) 2.7 (3.1 - 6.1) 
Abbreviations: BMI body mass index. eGFR estimated glomerular filtration rate. FVIII Factor VIII. CRP 
C-reactive protein. Continuous variables are presented as mean ± standard deviation (SD) unless noted. 
Frequency are presented as percentages unless noted.  
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Table 3.2.: Association of eGFR and biomarkers of inflammation and 
procoagulation in the cohort sample 
 Difference in biomarker (95% CI)  
per 10 ml/min/1.73m2 lower eGFR 
 Unadjusted  Adjusted  
D-dimer (µg/ml) 0.12 (0.09, 0.15) 0.05 (0.01, 0.08) 
FVIII (%) 5.8 (4.5, 7.1) 6.4 (4.5, 8.4) 
CRP (mg/L) 0.07 (0.03, 0.11) 0.09 (0.04, 0.15) 
Abbrevations: CI, confidence interval; eGFR, estimated glomerular filtration 
rate; FVIII, Factor VIII; CRP, C-reactive protein. Linear regression models were 
adjusted for age, sex, race, region, BMI, hypertension, diabetes, hyperlipidemia, 
cardiovascular disease, smoking. D-dimer and CRP were highly skewed and 
were log transformed. 
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Table 3.3.: Association of biomarkers and risk of VTE 
 HR (95% CI) per SD increment of each biomarker 
 Unadjusted Adjusted 
D-dimer 1.77 (1.51, 2.07) 1.69 (1.41, 2.02) 
FVIII 2.14 (1.80, 2.53) 2.23 (1.89, 2.62) 
CRP 1.34 (1.16, 1.56) 1.29 (1.09, 1.52) 
Abbreviations: HR, hazard ratio; CI, confidence interval; SD, standard deviation; 
FVIII, Factor VIII; CRP, C-reactive protein. Cox models were adjusted for age, sex, 
race, region, race*region and BMI. D-dimer and CRP were log transformed. 
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Table 3.4.: Association of eGFR and incident VTE with adjustment for biomarkers of procoagulation and inflammation  
Model HR (95% CI) of VTE 
per 10-unit lower 
eGFR 
HR (95% CI) of VTE by quartile of eGFR (ml/min/1.73m2) 
Q1  
(7-≤71) 
Q2  
(>71-≤87) 
Q3  
(>87-≤103) 
Q4  
(>103-107) 
Case-Cohort Study      
Cases (n)  66 74 60 47 
Cohort sample (n)  233 225 239 252 
Base Model* 1.13 (1.02, 1.25) 1.39 (0.77, 2.49) 1.19 (0.71, 2.01) 1.06 (0.65, 1.74) 1.0 
Base Model + D-dimer 1.10 (0.99, 1.21) 1.12 (0.62, 2.05) 1.11 (0.65, 1.91) 1.06 (0.64, 1.76) 1.0 
Base Model + FVIII  0.98 (0.87, 1.11) 0.69 (0.35, 1.37) 0.60 (0.32, 1.11) 0.86 (0.50, 1.48) 1.0 
Base Model + CRP 1.11 (1.00, 1.22) 1.24 (0.68, 2.24) 1.15 (0.69, 1.94) 1.03 (0.63, 1.69) 1.0 
Full Cohort      
Base Model 1.09 (1.02, 1.16) 1.46 (0.91, 2.36) 1.13 (0.72, 1.80) 0.97 (0.61, 1.54) 1.0 
Base Model + CRP 1.07 (1.00, 1.15) 1.36 (0.84, 2.19) 1.09 (0.69, 1.72) 0.96 (0.60, 1.52) 1.0 
Abbreviations: HR, hazard ratio; CI, confidence interval; Q, quartile; FVIII, Factor VIII; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate. 
eGFR as a predictor is presented as a continuous variable (HR per 10 ml/min/1.73m2 decrement) and as quartiles with reference group as the highest quartile 
of eGFR. Cox models were adjusted for age, sex, race, region, race*region and BMI (Base Model*) and biomarkers individually. D-dimer and CRP were log 
transformed.  
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Table 3.5.: The association of lifestyle factors and medications with the risk of VTE, stratified by CKD status 
  HR (95% CI) of VTE P interaction of 
Protective Factor x 
CKD Status   Overall  
(n = 25,936) 
CKD  
(n = 2,473) 
No CKD  
(n = 23,463) 
Regular Aspirin Use N cases 
N non-cases 
 
 
124 
11,059 
1.08 (0.81, 1.43) 
22 
1,341 
0.96 (0.51, 1.79) 
102 
9,718 
1.07 (0.80, 1.41) 
 
 
0.64 
Statin Use N cases 
N non-cases 
 
 
70 
8,005 
0.68 (0.50, 0.93) 
16 
1,078 
0.86 (0.46, 1.64) 
54 
6,927 
0.67 (0.49, 0.93) 
 
 
0.61 
Warfarin Use N cases 
N non-cases 
 
 
4 
704 
0.30 (0.07, 1.21) 
2 
177 
0.70 (0.17, 2.94) 
2 
527 
0.29 (0.07, 1.19) 
 
 
0.41 
Physical activity 
1-3 x/week vs none 
 
N cases 
N non-cases 
 
 
83 
9,214 
0.82 (0.59, 1.14) 
12 
700 
0.88 (0.43, 1.81) 
71 
8,514 
0.82 (0.59, 1.14) 
 
 
 
 
0.98 Physical activity 
4+/week vs none 
N cases 
N non-cases 
 
 
66 
7,622 
0.76 (0.53, 1.07) 
8 
539 
0.73 (0.32, 1.67) 
58 
7,083 
0.76 (0.53, 1.08) 
BMI<25 vs 25 
 
N cases 
N non-cases 
 
41 
6,410 
0.48 (0.32, 0.70) 
10 
545 
1.07 (0.51, 2.22) 
31 
5,865 
0.47 (0.32, 0.70) 
 
 
0.07 
CKD is defined as eGFR < 60 ml/min/1.73m2. Models were adjusted for age, sex, race, region, race*region, BMI. 
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Table 3.6.: (Supplemental Table S3.1): Exclusion criteria  
 
 
Exclusion Criteria Cohort Random 
Sample  
N=1,081 
VTE 
cases 
N=386 
Case-Cohort 
Sample 
 N=1,467 
Full Cohort 
 
N=30,239 
Missing follow up    -684 
Missing renal function -72 -16 -88 -1767 
Missing biomarker -6 -3 -9 n/a 
Receiving dialysis -3 -5 -8 -113 
Baseline VTE -61 -68 -129 -1739 
Final Cohort 939 294 1,233 25,936 
 98 
 
Table 3.7.: (Supplemental Table S3.2): Methodological approaches to studying analytic drift in 
REGARDS case-cohort study of VTE risk 
Approach Sample set Duplicates  LITE study 
Description Purchased set of donor 
samples are run along 
with each new set of 
analytes (FVIII and D-
dimer in 2012 and 2015 
with CRS and VTE 
cases, respectively) 
FVIII and D-dimer were 
run in the CRS in 2012. 
All VTE cases were run 
in 2015. Some 
participants of the CRS 
developed VTE and had 
duplicate analytes in 
2015.  
 
D-dimer only. Two 
analyzers were used 
(Sta-R and Evolution). 
Repeat measures 
performed in 888 
samples on both 
analyzers in 2014 over 
5-day period.  
Number of analytes 20 59 
 
700 
Results -D-dimer was 0.10 
µg/ml higher in 2015 vs 
2012. Mean CV was 
39.7% (range 5.4-
73.9%). No difference 
comparing freeze thaw 
cycles x1 vs x5 in 2015 
(r = 0.99; R2= 0.98). 
 
-FVIII levels did not 
change over time. Mean 
CV 6.7% (5.11-
21.30%).  
-D-dimer was 0.06 
µg/ml higher in 2015 
(Evolution) vs 2012 
(Sta-R). r = 1.00; R2= 
0.97 
 
-mean FVIII 26% higher 
in 2015. r = 0.84; R2= 
0.71 
-D-dimer was 0.05 
µg/ml higher in 
Evolution vs Sta-R).  
r = 0.97; R2= 0.93. 
 
Abbreviations: FVIII, Factor VIII; CRS, cohort random sample; vs, versus; r, correlation coefficient; R2, 
coefficient of determination; LITE, Longitudinal Investigation of Thromboembolism Etiology study. 
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Table 3.8.: (Supplemental Table S3.3): Association of eGFR and VTE at 1, 3, 5 years follow up  
   
HR (95% CI) of VTE per 10 ml/min/1.73m2 
  Year 1 Year 3 Year 5 
Case-Cohort N cases, cumulative 26 110 198 
 Base model 1.23 (1.11, 1.37) 1.13 (1.05, 1.22) 1.04 (0.95, 1.14) 
 Base + FVIII 1.10 (0.94, 1.29) 1.00 (0.89, 1.13) 0.91 (0.79, 1.06) 
Full Cohort* N cases, cumulative 25 108 250 
 Base model 1.18 (1.06, 1.31 1.10 (1.03, 1.18) 1.03 (0.94, 1.12) 
Abbreviations: HR, hazard ratio; CI, confidence interval; FVIII, Factor VIII; eGFR, estimated glomerular filtration rate. Base 
model includes age, sex, race, region, race*region and BMI. *FVIII was not measured in the full cohort.  
 
 100 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.: Potential mediators of the association of eGFR and Venous 
Thromboembolism: Role of biomarkers of inflammation and procoagulation 
 
 
CKD VTE 
FVIII 100% (50-100%) 
D-Dimer 23% (5-100%) 
CRP 22% (5-69%) 
Unexplained factors 
Inflammation and 
procoagulation 
 101 
 
References 
1. Cheung KL, Zakai NA, Folsom AR, Kurella Tamura M, Peralta CA, Judd SE, 
Callas PW, Cushman M. Measures of Kidney Disease and the Risk of Venous 
Thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in 
Stroke) Study. American journal of kidney diseases : the official journal of the National 
Kidney Foundation. 2017;70:182-90. 
2. Mahmoodi BK, Gansevoort RT, Naess IA, Lutsey PL, Braekkan SK, Veeger NJ, 
Brodin EE, Meijer K, Sang Y, Matsushita K, Hallan SI, Hammerstrom J, Cannegieter SC, 
Astor BC, Coresh J, Folsom AR, Hansen JB, Cushman M. Association of mild to 
moderate chronic kidney disease with venous thromboembolism: pooled analysis of five 
prospective general population cohorts. Circulation. 2012;126:1964-71. 
3. Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. 
Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial 
Transplant. 2010;25:3296-301. 
4. Ocak G, Vossen CY, Lijfering WM, Verduijn M, Dekker FW, Rosendaal FR, 
Cannegieter SC. Role of hemostatic factors on the risk of venous thrombosis in people 
with impaired kidney function. Circulation. 2014;129:683-91. 
5. Dubin R, Cushman M, Folsom AR, Fried LF, Palmas W, Peralta CA, Wassel C, 
Shlipak MG. Kidney function and multiple hemostatic markers: cross sectional 
associations in the multi-ethnic study of atherosclerosis. BMC Nephrol. 2011;12:3. 
6. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney 
function with inflammatory and procoagulant markers in a diverse cohort: a cross-
sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC 
Nephrol. 2008;9:9. 
7. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg 
CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly 
persons with renal insufficiency. Circulation. 2003;107:87-92. 
8. Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, 
Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 
2003;101:1243-8. 
9. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti 
G, Poli D, Tait RC, Iorio A. Patient-level meta-analysis: effect of measurement timing, 
threshold, and patient age on ability of D-dimer testing to assess recurrence risk after 
unprovoked venous thromboembolism. Annals of internal medicine. 2010;153:523-31. 
10. Folsom AR, Cushman M, Heckbert SR, Rosamond WD, Aleksic N. Prospective 
study of fibrinolytic markers and venous thromboembolism. Journal of clinical 
epidemiology. 2003;56:598-603. 
11. Marcucci M, Smith CT, Douketis JD, Tosetto A, Baglin T, Cushman M, 
Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level compared with study-level 
meta-analyses demonstrate consistency of D-dimer as predictor of venous 
thromboembolic recurrences. Journal of clinical epidemiology. 2013;66:415-25. 
12. Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, 
Bauer KA, Kessler CM, Cushman M. D-dimer, factor VIII coagulant activity, low-
 102 
 
intensity warfarin and the risk of recurrent venous thromboembolism. Journal of 
thrombosis and haemostasis : JTH. 2006;4:1208-14. 
13. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, 
Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous 
unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of 
thrombosis and haemostasis : JTH. 2012;10:1019-25. 
14. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous 
thromboembolism. A prospective investigation in the ARIC cohort. Thrombosis and 
haemostasis. 2009;102:615-9. 
15. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, 
Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: 
the longitudinal investigation of thromboembolism etiology (LITE). The American 
journal of medicine. 2002;113:636-42. 
16. Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, Tracy RP, Folsom 
AR, Zakai NA. Inflammation markers and incident venous thromboembolism: the 
REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. Journal 
of thrombosis and haemostasis : JTH. 2014;12:1993-2001. 
17. Luxembourg B, Schmitt J, Humpich M, Glowatzki M, Dressler D, Seifried E, 
Lindhoff-Last E. Cardiovascular risk factors in idiopathic compared to risk-associated 
venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-
reactive protein (hs-CRP). Thrombosis and haemostasis. 2009;102:668-75. 
18. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van 
den Ende A, Buller HR. High plasma concentration of factor VIIIc is a major risk factor 
for venous thromboembolism. Thrombosis and haemostasis. 2000;83:5-9. 
19. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of 
clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein 
thrombosis. Lancet. 1995;345:152-5. 
20. Olson NC, Cushman M, Judd SE, McClure LA, Lakoski SG, Folsom AR, 
Safford MM, Zakai NA. American Heart Association's Life's Simple 7 and risk of venous 
thromboembolism: the Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study. J Am Heart Assoc. 2015;4:e001494. 
21. Kabrhel C, Varraso R, Goldhaber SZ, Rimm E, Camargo CA, Jr. Physical 
inactivity and idiopathic pulmonary embolism in women: prospective study. Bmj. 
2011;343:d3867. 
22. Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, Heinze G, 
Kyrle PA. Overweight, obesity, and the risk of recurrent venous thromboembolism. 
Archives of internal medicine. 2008;168:1678-83. 
23. Li L, Zhang P, Tian JH, Yang K. Statins for primary prevention of venous 
thromboembolism. Cochrane Database Syst Rev. 2014:CD008203. 
24. Lassila R, Jula A, Pitkaniemi J, Haukka J. The association of statin use with 
reduced incidence of venous thromboembolism: a population-based cohort study. BMJ 
open. 2014;4:e005862. 
25. Herrington DM, Vittinghoff E, Lin F, Fong J, Harris F, Hunninghake D, Bittner 
V, Schrott HG, Blumenthal RS, Levy R, Group HS. Statin therapy, cardiovascular events, 
 103 
 
and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). 
Circulation. 2002;105:2962-7. 
26. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P. Effect of statin 
therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation 
(PRINCE): a randomized trial and cohort study. JAMA : the journal of the American 
Medical Association. 2001;286:64-70. 
27. Adams NB, Lutsey PL, Folsom AR, Herrington DH, Sibley CT, Zakai NA, 
Ades S, Burke GL, Cushman M. Statin therapy and levels of hemostatic factors in a 
healthy population: the Multi-Ethnic Study of Atherosclerosis. Journal of thrombosis and 
haemostasis : JTH. 2013;11:1078-84. 
28. Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GY, Muntner P, Bittner V, 
Ray KK, Watts GF, Hovingh GK, Rysz J, Kastelein JJ, Banach M, Lipid, Blood Pressure 
Meta-analysis Collaboration G. Association between statin use and plasma D-dimer 
levels. A systematic review and meta-analysis of randomised controlled trials. 
Thrombosis and haemostasis. 2015;114:546-57. 
29. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A, 
Moy CS, Howard G. The reasons for geographic and racial differences in stroke study: 
objectives and design. Neuroepidemiology. 2005;25:135-43. 
30. Gillett SR, Boyle RH, Zakai NA, McClure LA, Jenny NS, Cushman M. 
Validating laboratory results in a national observational cohort study without field 
centers: the Reasons for Geographic and Racial Differences in Stroke cohort. Clinical 
biochemistry. 2014;47:243-6. 
31. Zakai NA, McClure LA, Judd SE, Safford MM, Folsom AR, Lutsey PL, 
Cushman M. Racial and regional differences in venous thromboembolism in the United 
States in 3 cohorts. Circulation. 2014;129:1502-9. 
32. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, 
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ckd EPI. A new equation to 
estimate glomerular filtration rate. Annals of internal medicine. 2009;150:604-12. 
33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, 
Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. Estimating 
Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal 
of Medicine. 2012;367:20-9. 
34. Cushman M, Judd SE, Howard VJ, Kissela B, Gutierrez OM, Jenny NS, Ahmed 
A, Thacker EL, Zakai NA. N-terminal pro-B-type natriuretic peptide and stroke risk: the 
reasons for geographic and racial differences in stroke cohort. Stroke; a journal of 
cerebral circulation. 2014;45:1646-50. 
35. Suzuki T, Voeks J, Zakai NA, Jenny NS, Brown TM, Safford MM, LeWinter M, 
Howard G, Cushman M. Metabolic syndrome, C-reactive protein, and mortality in U.S. 
Blacks and Whites: the Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study. Diabetes Care. 2014;37:2284-90. 
36. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. 
Journal of clinical epidemiology. 1999;52:1165-72. 
 104 
 
37. Robert-Ebadi H, Bertoletti L, Combescure C, Le Gal G, Bounameaux H, Righini 
M. Effects of impaired renal function on levels and performance of D-dimer in patients 
with suspected pulmonary embolism. Thrombosis and haemostasis. 2014;112:614-20. 
38. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball 
S, Townend JN, Baigent C. Inflammation, endothelial dysfunction, and platelet activation 
in patients with chronic kidney disease: the chronic renal impairment in Birmingham 
(CRIB) study. American journal of kidney diseases : the official journal of the National 
Kidney Foundation. 2004;43:244-53. 
39. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, 
Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with 
moderate to severe chronic kidney disease. Kidney international. 2004;65:1009-16. 
40. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role 
of the low density lipoprotein-related protein receptor in mediation of factor VIII 
catabolism. The Journal of biological chemistry. 1999;274:37685-92. 
41. Milani L, Merkel C, Canel F, Gasparotto ML, Gatta A. Relationship between 
plasma levels of factor VIII related antigen and reticulo-endothelial function in chronic 
uremia. Clinical nephrology. 1983;20:235-8. 
42. Kim C, Vaziri ND. Down-regulation of hepatic LDL receptor-related protein 
(LRP) in chronic renal failure. Kidney international. 2005;67:1028-32. 
43. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, 
Savage PJ. Fibrinogen and factor VIII, but not factor VII, are associated with measures of 
subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health 
Study. Arteriosclerosis, thrombosis, and vascular biology. 1995;15:1269-79. 
44. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor 
VIII, ABO blood group and the incidence of ischaemic heart disease. British journal of 
haematology. 1994;88:601-7. 
45. Tin A, Grams ME, Maruthur NM, Astor BC, Couper D, Mosley TH, Fornage M, 
Parekh RS, Coresh J, Kao WH. Hemostatic Factors, APOL1 Risk Variants, and the Risk 
of ESRD in the Atherosclerosis Risk in Communities Study. Clinical journal of the 
American Society of Nephrology : CJASN. 2015;10:784-90. 
46. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. 
Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis 
Risk in Communities (ARIC) Study. American journal of kidney diseases : the official 
journal of the National Kidney Foundation. 2009;53:596-605. 
47. Hiramoto JS, Katz R, Peralta CA, Ix JH, Fried L, Cushman M, Siscovick D, 
Palmas W, Sarnak M, Shlipak MG. Inflammation and coagulation markers and kidney 
function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). American journal 
of kidney diseases : the official journal of the National Kidney Foundation. 2012;60:225-
32. 
48. Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, 
Beasley TM. Influence of kidney function on risk of supratherapeutic international 
normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. 
American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2015;65:701-9. 
 105 
 
49. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, 
Acton RT, Allon M. Kidney function influences warfarin responsiveness and 
hemorrhagic complications. Journal of the American Society of Nephrology : JASN. 
2009;20:912-21. 
50. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous 
thromboembolism: a systematic review and meta-analysis. The Lancet Haematology. 
2017;4:e83-e93. 
51. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. 
Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal 
investigation of thromboembolism etiology. Archives of internal medicine. 
2002;162:1182-9. 
 
 106 
 
Comprehensive References:  
Abbott KC, Cruess DF, Agodoa LY, Sawyers ES, Tveit DP. Early renal insufficiency and 
late venous thromboembolism after renal transplantation in the United States. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 
2004;43(1):120-130. 
 
Abdelmalek JA, Gansevoort RT, Lambers Heerspink HJ, Ix JH, Rifkin DE. Estimated 
albumin excretion rate versus urine albumin-creatinine ratio for the assessment of 
albuminuria: a diagnostic test study from the Prevention of Renal and Vascular Endstage 
Disease (PREVEND) Study. American journal of kidney diseases : the official journal of 
the National Kidney Foundation. 2014;63(3):415-421. 
 
Ahn S, Kim MH, Jun KW, et al. The incidence and risk factors for deep vein thrombosis 
after kidney transplantation in Korea: single-center experience. Clinical transplantation. 
2015;29(12):1181-1186. 
 
Alanan U, Abbas A, Sulaiman I. Relationship between ABO blood group and end-stage 
renal disease in Latakia, Syria. Saudi journal of kidney diseases and transplantation : an 
official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 
2017;28(2):445. 
 
Alexander KS, Zakai NA, Gillett S, et al. ABO blood type, factor VIII, and incident 
cognitive impairment in the REGARDS cohort. Neurology. 2014;83(14):1271-1276. 
 
Bagot CN, Arya R. Virchow and his triad: a question of attribution. British journal of 
haematology. 2008;143(2):180-190. 
 
Banach M, Bromfield S, Howard G, et al. Association of systolic blood pressure levels 
with cardiovascular events and all-cause mortality among older adults taking 
antihypertensive medication. International journal of cardiology. 2014;176(1):219-226. 
 
Barbalic M, Dupuis J, Dehghan A, et al. Large-scale genomic studies reveal central role 
of ABO in sP-selectin and sICAM-1 levels. Human molecular genetics. 2010;19(9):1863-
1872. 
 
Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently 
associated with mortality in both hemodialysis and pre-dialysis patients with chronic 
kidney disease. Kidney international. 2010;77(6):550-556. 
 
Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, 
hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in 
Communities (ARIC) Study. American journal of kidney diseases : the official journal of 
the National Kidney Foundation. 2009;53(4):596-605. 
 107 
 
Beck LH, Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as 
target antigen in idiopathic membranous nephropathy. The New England journal of 
medicine. 2009;361(1):11-21. 
 
Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public 
health concern. American journal of preventive medicine. 2010;38(4 Suppl):S495-501. 
 
Bern MM, Klumpar DI, Wheeler WE, Davis GL. Factor VIII complex in chronic renal 
failure: influence of protein C, fibrinolysis and diabetes mellitus. Thrombosis research. 
1983;31(1):177-186. 
 
Bovenschen N, Boertjes RC, van Stempvoort G, et al. Low density lipoprotein receptor-
related protein and factor IXa share structural requirements for binding to the A3 domain 
of coagulation factor VIII. The Journal of biological chemistry. 2003;278(11):9370-9377. 
 
Bovenschen N, Herz J, Grimbergen JM, et al. Elevated plasma factor VIII in a mouse 
model of low-density lipoprotein receptor-related protein deficiency. Blood. 
2003;101(10):3933-3939. 
 
Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von 
Willebrand factor by ADAMTS13. Journal of thrombosis and haemostasis : JTH. 
2003;1(1):33-40. 
 
Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor 
IXa: active site and module structure related to Xase activity and hemophilia B. 
Proceedings of the National Academy of Sciences of the United States of America. 
1995;92(21):9796-9800. 
 
Brodin EE, Braekkan SK, Vik A, Brox J, Hansen JB. Cystatin C is associated with risk of 
venous thromboembolism in subjects with normal kidney function--the Tromso study. 
Haematologica. 2012;97(7):1008-1013. 
 
Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates 
proteolytic cleavage of von Willebrand factor by ADAMTS13. Proceedings of the 
National Academy of Sciences of the United States of America. 2008;105(21):7416-
7421. 
 
Casonato A, Pontara E, Vertolli UP, et al. Plasma and platelet von Willebrand factor 
abnormalities in patients with uremia: lack of correlation with uremic bleeding. Clinical 
and applied thrombosis/hemostasis : official journal of the International Academy of 
Clinical and Applied Thrombosis/Hemostasis. 2001;7(2):81-86. 
 
Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL. Short-term 
intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in 
 108 
 
Communities Intraindividual Variability Study. Annals of epidemiology. 1992;2(5):723-
733. 
 
Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for 
measuring factor VIII levels in plasma. American journal of clinical pathology. 
2003;120(1):34-39. 
 
Chang SJ, Koh SB, Cha BS, Park JK. Job characteristics and blood coagulation factors in 
Korean male workers. Journal of occupational and environmental medicine / American 
College of Occupational and Environmental Medicine. 2002;44(11):997-1002. 
Chapter 1: Definition and classification of CKD. Kidney International 
Supplements.3(1):19-62. 
 
Chen Q, Shou W, Wu W, et al. Biological and analytical variations of 16 parameters 
related to coagulation screening tests and the activity of coagulation factors. Seminars in 
thrombosis and hemostasis. 2015;41(3):336-341. 
 
Chen Z, Yang S-H, Xu H, Li J-J. ABO blood group system and the coronary artery 
disease: an updated systematic review and meta-analysis. Scientific reports. 
2016;6:23250. 
 
Cheung KL, Zakai NA, Callas PW, et al. Mechanisms and mitigating factors for venous 
thromboembolism in chronic kidney disease: the REGARDS study. Submitted. 2018. 
 
Cheung KL, Zakai NA, Folsom AR, et al. Measures of Kidney Disease and the Risk of 
Venous Thromboembolism in the REGARDS (Reasons for Geographic and Racial 
Differences in Stroke) Study. American journal of kidney diseases : the official journal of 
the National Kidney Foundation. 2017;70(2):182-190. 
 
Christiansen CF, Schmidt M, Lamberg AL, et al. Kidney disease and risk of venous 
thromboembolism: a nationwide population-based case-control study. Journal of 
thrombosis and haemostasis : JTH. 2014;12(9):1449-1454. 
 
Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand 
factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in 
Communities (ARIC) Study. Thrombosis and haemostasis. 1993;70(3):380-385. 
 
Coppola R, Guerra L, Ruggeri ZM, Tarantino A, Mannucci PM, Ponticelli C. Factor 
VIII/von Willebrand factor in glomerular nephropathies. Clinical nephrology. 
1981;16(5):217-222. 
 
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United 
States. JAMA. 2007;298(17):2038-2047. 
 109 
 
Cucuianu M, Trif I, Roman S, Manasia M, Spinu C, Cristea A. Plasma von Willebrand 
factor antigen and activity and platelet aggregability in patients with proteinuria. 
Medecine interne. 1989;27(4):263-271. 
 
Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future 
venous thrombosis. Blood. 2003;101(4):1243-1248. 
 
Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism 
in two cohorts: the longitudinal investigation of thromboembolism etiology. The 
American journal of medicine. 2004;117(1):19-25. 
 
de Maat MP, van Schie M, Kluft C, Leebeek FW, Meijer P. Biological Variation of 
Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance 
Specifications. Clinical chemistry. 2016;62(12):1639-1646. 
 
Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. 
Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 
1989;32(4):219-226. 
 
Do H, Healey JF, Waller EK, Lollar P. Expression of Factor VIII by Murine Liver 
Sinusoidal Endothelial Cells. Journal of Biological Chemistry. 1999;274(28):19587-
19592. 
 
Domingueti CP, Dusse LM, Foscolo RB, et al. Von Willebrand Factor, ADAMTS13 and 
D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes 
Mellitus. PloS one. 2015;10(7):e0132784. 
 
Domingueti CP, Foscolo RB, Reis JS, et al. Association of Haemostatic and 
Inflammatory Biomarkers with Nephropathy in Type 1 Diabetes Mellitus. Journal of 
diabetes research. 2016;2016:2315260. 
 
Dubin R, Cushman M, Folsom AR, et al. Kidney function and multiple hemostatic 
markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC 
Nephrol. 2011;12:3. 
 
Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. 
Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with 
activation and inactivation of factor VIII coagulant activity. Biochemistry. 
1986;25(2):505-512. 
 
Esmon CT. Inflammation and thrombosis. Journal of thrombosis and haemostasis : JTH. 
2003;1(7):1343-1348. 
 
 110 
 
Fang H, Wang L, Wang H. The protein structure and effect of factor VIII. Thrombosis 
research. 2007;119(1):1-13. 
 
Fay PJ, Smudzin TM. Characterization of the interaction between the A2 subunit and 
A1/A3-C1-C2 dimer in human factor VIIIa. The Journal of biological chemistry. 
1992;267(19):13246-13250. 
 
Fellstrom B, Siegbahn A, Liljenberg G, et al. Primary haemostasis, plasmatic coagulation 
and fibrinolysis in renal transplantation. Thrombosis research. 1990;59(1):97-104. 
 
Fioretto P, Stehouwer CD, Mauer M, et al. Heterogeneous nature of microalbuminuria in 
NIDDM: studies of endothelial function and renal structure. Diabetologia. 
1998;41(2):233-236. 
 
Folsom AR, Lutsey PL, Astor BC, Wattanakit K, Heckbert SR, Cushman M. Chronic 
kidney disease and venous thromboembolism: a prospective study. Nephrol Dial 
Transplant. 2010;25(10):3296-3301. 
 
Foster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of 
CKD among African Americans. Journal of the American Society of Nephrology : JASN. 
2013;24(9):1484-1491. 
 
Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO 
blood group and von Willebrand factor levels: from biology to clinical implications. 
Thrombosis Journal. 2007;5:14-14. 
 
Gale AJ, Cramer TJ, Rozenshteyn D, Cruz JR. Detailed Mechanisms of the Inactivation 
of Factor VIIIa by Activated Protein C in the Presence of Its Cofactors, Protein S and 
Factor V. The Journal of biological chemistry. 2008;283(24):16355-16362. 
 
Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival 
in O blood group subjects explains how ABO determinants influence plasma von 
Willebrand factor. Blood. 2008;111(7):3540-3545. 
 
Genovese G, Friedman DJ, Ross MD, et al. Association of Trypanolytic ApoL1 Variants 
with Kidney Disease in African Americans. Science. 2010;329(5993):841-845. 
 
Gigante B, Strawbridge RJ, Velasquez IM, et al. Analysis of the Role of Interleukin 6 
Receptor Haplotypes in the Regulation of Circulating Levels of Inflammatory 
Biomarkers and Risk of Coronary Heart Disease. PloS one. 2015;10(3):e0119980. 
 
Gillett SR, Boyle RH, Zakai NA, McClure LA, Jenny NS, Cushman M. Validating 
laboratory results in a national observational cohort study without field centers: the 
 111 
 
Reasons for Geographic and Racial Differences in Stroke cohort. Clinical biochemistry. 
2014;47(16-17):243-246. 
 
Gimelli S, Caridi G, Beri S, et al. Mutations in SOX17 are associated with congenital 
anomalies of the kidney and the urinary tract. Human mutation. 2010;31(12):1352-1359. 
 
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. The New England journal of 
medicine. 2004;351(13):1296-1305. 
 
Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden 
of incident venous thromboembolism in the United States: A review of estimated 
attributable healthcare costs. Thrombosis research. 2016;137:3-10. 
 
Halanych JH, Shuaib F, Parmar G, et al. Agreement on cause of death between proxies, 
death certificates, and clinician adjudicators in the Reasons for Geographic and Racial 
Differences in Stroke (REGARDS) study. American journal of epidemiology. 
2011;173(11):1319-1326. 
 
Hamed IA, Mandal AK, Parker D, Czerwinski AW, Mask DR, Wenzl JE. ABO blood 
groups and renal disease. Annals of clinical and laboratory science. 1979;9(6):524-526. 
 
Hasson. Study the relationship between hemodialysis (HD) patients and their ABO blood 
grouping as well as screening of hemodialysis access-related bacterial infections. Current 
Research Journal of Biological Sciences. 2013;5(6):291-295. 
 
Hiramoto JS, Katz R, Peralta CA, et al. Inflammation and coagulation markers and 
kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 
2012;60(2):225-232. 
 
Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P. 
Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study 
in Europe. Haemophilia : the official journal of the World Federation of Hemophilia. 
2016;22(2):248-255. 
 
Horibe H, Fujimaki T, Oguri M, et al. Association of a polymorphism of the interleukin 6 
receptor gene with chronic kidney disease in Japanese individuals. Nephrology. 
2015;20(4):273-278. 
 
Howard MA, Whitworth JA, Hendrix LE, Thomas KB, Firkin BG. Abnormal factor VIII 
in chronic renal failure. The Medical journal of Australia. 1979;1(5):148-151. 
 112 
 
Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial 
differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135-
143. 
 
Huang MJ, Wei RB, Zhao J, et al. Albuminuria and Endothelial Dysfunction in Patients 
with Non-Diabetic Chronic Kidney Disease. Medical science monitor : international 
medical journal of experimental and clinical research. 2017;23:4447-4453. 
 
Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and 
pulmonary embolism. Journal of thrombosis and haemostasis : JTH. 2013;11(3):412-422. 
 
Huser B, Lammle B, Landmann J, et al. von Willebrand factor and factor VIII in renal 
transplant recipients under immunosuppression with cyclosporine and steroids. 
Sequential measurements over 4 months in 17 patients. Clinical nephrology. 
1990;34(5):214-222. 
 
Inker LA, Schmid CH, Tighiouart H, et al. Estimating Glomerular Filtration Rate from 
Serum Creatinine and Cystatin C. New England Journal of Medicine. 2012;367(1):20-29. 
 
Ix JH, Wassel CL, Stevens LA, et al. Equations to Estimate Creatinine Excretion Rate: 
The CKD Epidemiology Collaboration. Clinical Journal of the American Society of 
Nephrology. 2011;6(1):184-191. 
 
Jenkins PV, O’Donnell James S. ABO blood group determines plasma von Willebrand 
factor levels: a biologic function after all? Transfusion. 2006;46(10):1836-1844. 
 
Kamphuisen PW, Eikenboom JC, Vos HL, et al. Increased levels of factor VIII and 
fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. 
Thromb Haemost. 1999;81(5):680-683. 
 
Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous Thromboembolism in Patients 
Hospitalized with Nephrotic Syndrome. The American journal of medicine. 
2008;121(3):226-230. 
 
Kazatchkine M, Sultan Y, Caen JP, Bariety J. Bleeding in renal failure: a possible cause. 
Br Med J. 1976;2(6036):612-615. 
 
Khaleghi M, Singletary LA, Kondragunta V, et al. Haemostatic markers are associated 
with measures of vascular disease in adults with hypertension. Journal of human 
hypertension. 2009;23(8):530-537. 
 
Kleber ME, Delgado G, Grammer TB, et al. Uric Acid and Cardiovascular Events: A 
Mendelian Randomization Study. Journal of the American Society of Nephrology : 
JASN. 2015;26(11):2831-2838. 
 113 
 
Kopitsky RG, Switzer ME, Williams RS, McKee PA. The basis for the increase in factor 
VIII procoagulant activity during exercise. Thrombosis and haemostasis. 1983;49(1):53-
57. 
 
Kosloski MP, Miclea RD, Balu-Iyer SV. Role of Glycosylation in Conformational 
Stability, Activity, Macromolecular Interaction and Immunogenicity of Recombinant 
Human Factor VIII. The AAPS journal. 2009;11(3):424. 
 
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor 
VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 
1995;345(8943):152-155. 
 
Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 
new loci associated with serum urate concentrations. Nature genetics. 2013;45(2):145-
154. 
 
Kulkarni R, Soucie JM, Evatt B. Renal disease among males with haemophilia. 
Haemophilia : the official journal of the World Federation of Hemophilia. 2003;9(6):703-
710. 
 
Kumar G, Sakhuja A, Taneja A, et al. Pulmonary embolism in patients with CKD and 
ESRD. Clinical journal of the American Society of Nephrology : CJASN. 
2012;7(10):1584-1590. 
 
Kurella Tamura M, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment 
in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) 
Study. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2008;52(2):227-234. 
 
Lai JD, Georgescu MT, Hough C, Lillicrap D. To clear or to fear: An innate perspective 
on factor VIII immunity. Cellular Immunology. 2016;301:82-89. 
 
Lam NN, Garg AX, Knoll GA, et al. Venous Thromboembolism and the Risk of Death 
and Graft Loss in Kidney Transplant Recipients. American journal of nephrology. 
2017;46(4):343-354. 
 
Lamphear BJ, Fay PJ. Proteolytic interactions of factor IXa with human factor VIII and 
factor VIIIa. Blood. 1992;80(12):3120-3126. 
 
Larson NB, Bell EJ, Decker PA, et al. ABO blood group associations with markers of 
endothelial dysfunction in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 
2016;251:422-429. 
 
 114 
 
Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. 
American journal of epidemiology. 2009;170(2):244-256. 
 
Lenting PJ, CJ VANS, Denis CV. Clearance mechanisms of von Willebrand factor and 
factor VIII. Journal of thrombosis and haemostasis : JTH. 2007;5(7):1353-1360. 
 
Lenting PJ, van Mourik JA, Mertens K. The Life Cycle of Coagulation Factor VIII in 
View of Its Structure and Function. Blood. 1998;92(11):3983-3996. 
 
Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor 
VIII. The Journal of biological chemistry. 1990;265(3):1688-1692. 
 
Lu GY, Shen L, Wang ZY, et al. Significance of plasma von Willebrand factor level and 
von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. 
Chinese medical journal. 2008;121(2):133-136. 
 
Lu GY, Xu RJ, Zhang SH, et al. Alteration of circulatory platelet microparticles and 
endothelial microparticles in patients with chronic kidney disease. International journal of 
clinical and experimental medicine. 2015;8(9):16704-16708. 
 
Mahmoodi BK, Gansevoort RT, Naess IA, et al. Association of mild to moderate chronic 
kidney disease with venous thromboembolism: pooled analysis of five prospective 
general population cohorts. Circulation. 2012;126(16):1964-1971. 
 
Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. Microalbuminuria and risk of venous 
thromboembolism. JAMA : the journal of the American Medical Association. 
2009;301(17):1790-1797. 
 
Mahmoodi BK, ten Kate MK, Waanders F, et al. High Absolute Risks and Predictors of 
Venous and Arterial Thromboembolic Events in Patients With Nephrotic Syndrome. 
Results From a Large Retrospective Cohort Study. 2008;117(2):224-230. 
 
Mann KG. Biochemistry and physiology of blood coagulation. Thrombosis and 
haemostasis. 1999;82(2):165-174. 
 
Margetic S. Inflammation and haemostasis. Biochemia Medica. 2012;22(1):49-62. 
 
Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide 
chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) 
structures. The Journal of biological chemistry. 1992;267(13):8723-8731. 
 
Menschikowski M, Hagelgans A, Schuler U, Froeschke S, Rosner A, Siegert G. Plasma 
levels of phospholipase A2-IIA in patients with different types of malignancies: 
 115 
 
prognosis and association with inflammatory and coagulation biomarkers. Pathology 
oncology research : POR. 2013;19(4):839-846. 
 
Milani L, Merkel C, Canel F, Gasparotto ML, Gatta A. Relationship between plasma 
levels of factor VIII related antigen and reticulo-endothelial function in chronic uremia. 
Clinical nephrology. 1983;20(5):235-238. 
 
Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood 
groups on primary hemostasis. Transfusion. 2001;41(1):56-60. 
 
Morange PE, Saut N, Antoni G, Emmerich J, Tregouet DA. Impact on venous thrombosis 
risk of newly discovered gene variants associated with FVIII and VWF plasma levels. 
Journal of thrombosis and haemostasis : JTH. 2011;9(1):229-231. 
 
Musso D, Robaina GI, Figueroa Cordoba AV, et al. Symptomatic Venous 
Thromboembolism and Major Bleeding After Renal Transplantation: Should We Use 
Pharmacologic Thromboprophylaxis? Transplantation proceedings. 2016;48(8):2773-
2778. 
 
National Chronic Kidney Disease Fact Sheet, 2017. Atlanta, GA: US Department of 
Health and Human Services Centers for Disease Control and Prevention; ;2017. 
 
Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor 
necrosis factor. The Journal of experimental medicine. 1986;163(3):740-745. 
 
Noe DA, Murphy PA, Bell WR, Siegel JN. Acute-phase behavior of factor VIII 
procoagulant and other acute-phase reactants in rabbits. The American journal of 
physiology. 1989;257(1 Pt 2):R49-56. 
 
O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C 
and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood. 
2000;95(5):1714-1720. 
 
Ocak G, Lijfering WM, Verduijn M, et al. Risk of venous thrombosis in patients with 
chronic kidney disease: identification of high-risk groups. Journal of thrombosis and 
haemostasis : JTH. 2013;11(4):627-633. 
 
Ocak G, van Stralen KJ, Rosendaal FR, et al. Mortality due to pulmonary embolism, 
myocardial infarction, and stroke among incident dialysis patients. Journal of thrombosis 
and haemostasis : JTH. 2012;10(12):2484-2493. 
 
Ocak G, Vossen CY, Lijfering WM, et al. Role of hemostatic factors on the risk of 
venous thrombosis in people with impaired kidney function. Circulation. 
2014;129(6):683-691. 
 116 
 
Office of the Surgeon General (US); National Heart L, and Blood Institute (US). The 
Surgeon General's Call to Action to Prevent Deep Venous Thrombosis and Pulmonary 
Embolism. 2008; http://www.ncbi.nlm.nih.gov/books/NBK44178/. Accessed November 
26, 2013. 
 
Ohira T, Cushman M, Tsai MY, et al. ABO blood group, other risk factors and incidence 
of venous thromboembolism: the Longitudinal Investigation of Thromboembolism 
Etiology (LITE). Journal of thrombosis and haemostasis : JTH. 2007;5(7):1455-1461. 
 
Olson NC, Cushman M, Lutsey PL, et al. Inflammation Markers and Incident Venous 
Thromboembolism: the REasons for Geographic And Racial Differences in Stroke 
(REGARDS) Cohort. Journal of thrombosis and haemostasis : JTH. 2014;12(12):1993-
2001. 
 
Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and 
factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII 
level. American journal of human genetics. 1985;37(1):89-101. 
 
P Girma J, Fressinaud E, Houllier A, Laurian Y, Amiral J, Meyer D. Assay of factor VIII 
antigen (VIII:CAg) in 294 Haemophilia A patients by a new commercial ELISA using 
monoclonal antibodies. Vol 41998. 
 
Pan J, Dinh TT, Rajaraman A, et al. Patterns of expression of factor VIII and von 
Willebrand factor by endothelial cell subsets in vivo. Blood. 2016;128(1):104-109. 
 
Poli D, Zanazzi M, Antonucci E, et al. Renal transplant recipients are at high risk for both 
symptomatic and asymptomatic deep vein thrombosis. Journal of thrombosis and 
haemostasis : JTH. 2006;4(5):988-992. 
 
Previato G, Loschiavo C, Lupo A, et al. Clinical significance of plasma factor VIII levels 
in renal disease. Clinical nephrology. 1981;16(4):200-206. 
 
Qi L, Cornelis MC, Kraft P, et al. Genetic variants in ABO blood group region, plasma 
soluble E-selectin levels and risk of type 2 diabetes. Human molecular genetics. 
2010;19(9):1856-1862. 
 
Ramalho JS, Tolmachova T, Hume AN, et al. Chromosomal mapping, gene structure and 
characterization of the human and murine RAB27B gene. BMC genetics. 2001;2:2. 
 
Rasic S, Hadzovic-Dzuvo A, Rebic D, Valjevac A, Uncanin S. Endothelial dysfunction in 
uremic patients on continuous ambulatory peritoneal dialysis (CAPD). Bosnian journal of 
basic medical sciences / Udruzenje basicnih mediciniskih znanosti = Association of Basic 
Medical Sciences. 2011;11(3):153-157. 
 117 
 
Rasmi Y, Makhdoomi K, Farshid S, Kheradmand F. Seroprevalence of anti-Helicobacter 
pylori and anticytotoxin-associated gene A antibodies [corrected] according to ABO 
blood groups and rhesus status among hemodialysis patients. Iranian journal of kidney 
diseases. 2011;5(2):110-113. 
 
Reitsma PH, Branger J, Van Den Blink B, Weijer S, Van Der Poll T, Meijers JC. 
Procoagulant protein levels are differentially increased during human endotoxemia. 
Journal of thrombosis and haemostasis : JTH. 2003;1(5):1019-1023. 
 
Rios DR, Fernandes AP, Figueiredo RC, et al. Relationship between ABO blood groups 
and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing 
hemodialysis. Journal of thrombosis and thrombolysis. 2012;33(4):416-421. 
 
Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. Journal of Thrombosis and 
Haemostasis. 2009;7:301-304. 
 
Sabater-Ileal M, Huffman JE, de Vries PS, et al. Genome-wide association trans-ethnic 
meta-analyses identifies novel associations regulating coagulation Factor VIII and von 
Willebrand Factor plasma levels. Submitted. 2018. 
 
Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the 
low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. 
The Journal of biological chemistry. 1999;274(53):37685-37692. 
 
Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415-
3422. 
 
Sarafanov AG, Ananyeva NM, Shima M, Saenko EL. Cell surface heparan sulfate 
proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein 
receptor-related protein. The Journal of biological chemistry. 2001;276(15):11970-11979. 
 
Schachterle W, Badwe CR, Palikuqi B, et al. Sox17 drives functional engraftment of 
endothelium converted from non-vascular cells. Nature communications. 2017;8:13963. 
 
Schledzewski K, Geraud C, Arnold B, et al. Deficiency of liver sinusoidal scavenger 
receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired 
hepatic clearance of noxious blood factors. The Journal of clinical investigation. 
2011;121(2):703-714. 
 
Sedaghat S, de Vries PS, Boender J, et al. von Willebrand Factor, ADAMTS13 Activity, 
and Decline in Kidney Function: A Population-Based Cohort Study. American journal of 
kidney diseases : the official journal of the National Kidney Foundation. 2016;68(5):726-
732. 
 118 
 
Sekula P, Li Y, Stanescu HC, et al. Genetic risk variants for membranous nephropathy: 
extension of and association with other chronic kidney disease aetiologies. Nephrology, 
dialysis, transplantation : official publication of the European Dialysis and Transplant 
Association - European Renal Association. 2017;32(2):325-332. 
 
Shen LEI, Lu G, Dong N, Jiang L, Ma Z, Ruan C. Von Willebrand factor, ADAMTS13 
activity, TNF-α and their relationships in patients with chronic kidney disease. 
Experimental and therapeutic medicine. 2012;3(3):530-534. 
 
Shiba T, Makino I, Kawakami K, Kato I, Kobayashi T, Kaneko K. p-Cresyl sulfate 
suppresses lipopolysaccharide-induced anti-bacterial immune responses in murine 
macrophages in vitro. Toxicology letters. 2016;245:24-30. 
 
Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant 
biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107(1):87-92. 
 
Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von 
Willebrand factor multimers. Cell. 1986;46(2):185-190. 
 
Stirling D, Hannant WA, Ludlam CA. Transcriptional activation of the factor VIII gene 
in liver cell lines by interleukin-6. Thrombosis and haemostasis. 1998;79(1):74-78. 
 
Sun C, Molineros JE, Looger LL, et al. High-density genotyping of immune-related loci 
identifies new SLE risk variants in individuals with Asian ancestry. Nature genetics. 
2016;48(3):323-330. 
 
Sun H, Yang M, Sait AS, Drygalski A, Jackson S. Haematuria is not a risk factor of 
hypertension or renal impairment in patients with haemophilia. Haemophilia : the official 
journal of the World Federation of Hemophilia. 2016;22(4):549-555. 
 
Sun X, Feng J, Wu W, Peng M, Shi J. ABO blood types associated with the risk of 
venous thromboembolism in Han Chinese people: A hospital-based study of 200,000 
patients. Scientific reports. 2017;7:42925. 
 
The United States Renal Data System (USRDS) annual data report: Epidemiology of 
kidney disease in the United States. National Institutes of Health, National Institute of 
Diabetes and Digestive and Kidney Disease, Bethesda, MD2017. 
 
Tin A, Grams ME, Maruthur NM, et al. Hemostatic Factors, APOL1 Risk Variants, and 
the Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clinical Journal of 
the American Society of Nephrology. 2015. 
 
Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human 
antihaemophilic factor. Nature. 1984;312(5992):342-347. 
 119 
 
 
Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, 
and venous thromboembolism: the longitudinal investigation of thromboembolism 
etiology (LITE). Am J Med. 2002;113(8):636-642. 
 
Turner NA, Moake JL. Factor VIII Is Synthesized in Human Endothelial Cells, Packaged 
in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings. PloS one. 
2015;10(10):e0140740. 
 
Turney JH, Woods HF, Fewell MR, Weston MJ. Factor VIII complex in uraemia and 
effects of haemodialysis. British medical journal. 1981;282(6277):1653-1656. 
 
Tveit DP, Hshieh P, Cruess D, Agodoa LY, Welch PG, Abbott KC. Risk factors for 
pulmonary embolism in chronic dialysis patients. Journal of nephrology. 2002;15(3):241-
247. 
 
Tveit DP, Hypolite IO, Hshieh P, et al. Chronic dialysis patients have high risk for 
pulmonary embolism. American journal of kidney diseases : the official journal of the 
National Kidney Foundation. 2002;39(5):1011-1017. 
 
van Breevoort D, Snijders AP, Hellen N, et al. STXBP1 promotes Weibel-Palade body 
exocytosis through its interaction with the Rab27A effector Slp4-a. Blood. 
2014;123(20):3185-3194. 
 
van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa 
in the activation of bovine factor X. The Journal of biological chemistry. 
1981;256(7):3433-3442. 
 
van Schooten CJ, Shahbazi S, Groot E, et al. Macrophages contribute to the cellular 
uptake of von Willebrand factor and factor VIII in vivo. Blood. 2008;112(5):1704-1712. 
 
Vaziri ND, Shah GM, Winer RL, et al. Coagulation cascade, fibrinolytic system, 
antithrombin III, protein C and protein S in patients maintained on continuous 
ambulatory peritoneal dialysis. Thrombosis research. 1989;53(2):173-180. 
 
Vázquez-Huerta DI, Alvarez-Rodríguez BA, Topete-Reyes JF, et al. Tumor necrosis 
factor alpha -238 G/A and -308 G/A polymorphisms and soluble TNF-α levels in chronic 
kidney disease: correlation with clinical variables. International journal of clinical and 
experimental medicine. 2014;7(8):2111-2119. 
 
Virchow RC. Thrombosis and Emboli. Canton, MA: Science History Publications; 1998. 
 
Voigtmann B, Burchardt U. [ABO blood groups in patients with nephropathies]. 
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete. 1991;46(5):156-159. 
 120 
 
 
Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein C and 
protein S. Archives of biochemistry and biophysics. 1987;252(1):322-328. 
 
Wang IK, Shen TC, Muo CH, Yen TH, Sung FC. Risk of pulmonary embolism in 
patients with end-stage renal disease receiving long-term dialysis. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and Transplant Association 
- European Renal Association. 2017;32(8):1386-1393. 
 
Wannamethee SG, Shaper AG, Lowe GD, Lennon L, Rumley A, Whincup PH. Renal 
function and cardiovascular mortality in elderly men: the role of inflammatory, 
procoagulant, and endothelial biomarkers. European heart journal. 2006;27(24):2975-
2981. 
 
Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney 
disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19(1):135-
140. 
 
White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 
Suppl 1):I4-8. 
 
Wiesholzer M, Kitzwogerer M, Harm F, et al. Prevalence of preterminal pulmonary 
thromboembolism among patients on maintenance hemodialysis treatment before and 
after introduction of recombinant erythropoietin. American journal of kidney diseases : 
the official journal of the National Kidney Foundation. 1999;33(4):702-708. 
 
Wiggins KL, Smith NL, Glazer NL, et al. ABO Genotype and Risk of Thrombotic Events 
and Hemorrhagic Stroke. Journal of thrombosis and haemostasis : JTH. 2009;7(2):263-
269. 
 
Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor 
VIII mRNA and antigen in human liver and other tissues. Nature. 1985;317(6039):726-
729. 
 
Wolpin BM, Kabrhel C, Varraso R, et al. Prospective study of ABO blood type and the 
risk of pulmonary embolism in two large cohort studies. Thrombosis and haemostasis. 
2010;104(5):962-971. 
 
Wuttke M, Wong CS, Wuhl E, et al. Genetic loci associated with renal function measures 
and chronic kidney disease in children: the Pediatric Investigation for Genetic Factors 
Linked with Renal Progression Consortium. Nephrology, dialysis, transplantation : 
official publication of the European Dialysis and Transplant Association - European 
Renal Association. 2016;31(2):262-269. 
 
 121 
 
Yang G, De Staercke C, Hooper WC. The effects of obesity on venous 
thromboembolism: A review. Open journal of preventive medicine. 2012;2(4):499-509. 
 
Yasuda T, Saegusa C, Kamakura S, Sumimoto H, Fukuda M. Rab27 effector Slp2-a 
transports the apical signaling molecule podocalyxin to the apical surface of MDCK II 
cells and regulates claudin-2 expression. Molecular biology of the cell. 
2012;23(16):3229-3239. 
 
Younes N, Cleary PA, Steffes MW, et al. Comparison of urinary albumin-creatinine ratio 
and albumin excretion rate in the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications study. Clinical journal 
of the American Society of Nephrology : CJASN. 2010;5(7):1235-1242. 
 
Younes S, Mais A, Al-Abdallat E, et al. Frequency of blood groups among a sample of 
patients with renal failure at royal medical services. European Scientific Journal. 
2015;11(33):1857-7881. 
 
Zakai NA, Judd SE, Alexander K, et al. ABO Blood Type and Stroke Risk: The REasons 
for Geographic and Racial Differences in Stroke (REGARDS) Study. Journal of 
thrombosis and haemostasis : JTH. 2014;12(4):564-570. 
 
Zakai NA, McClure LA, Judd SE, et al. Racial and regional differences in venous 
thromboembolism in the United States in 3 cohorts. Circulation. 2014;129(14):1502-
1509. 
 
Zhou XJ, Nath SK, Qi YY, et al. Novel identified associations of RGS1 and RASGRP1 
variants in IgA Nephropathy. Scientific reports. 2016;6:35781. 
 
